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Hand1 gene expression is negatively regulated by the High Mobility Group A1
(HMGA1) proteins and is drastically reduced in human thyroid carcinomas.
4ABSTRACT
HMGA1 proteins play their major physiological role during embryonic
development and have a critical role in neoplastic transformation.
To identify new pathways in which HMGA1 is involved we searched for
genes regulated by HMGA1 proteins using microarray analysis in embryonic
stem (ES) cells bearing one or two disrupted hmga1 alleles. We identified 87
transcripts increased and 163 transcripts decreased of at least four fold in
hmga1-/- ES cells. For some of them an HMGA1-dose dependency was
observed, since an intermediate level was observed in the heterozygous ES
cells. When the expression analysis of these genes was extended to embryonic
fibroblasts and adult tissues, such as heart, spleen and liver, from hmga1-
knockout mice, contrasting results were obtained. In fact, aside some genes
showing the same HMGA1 regulation observed in ES cells, there were some
genes that did not modify their expression, and some other showing a
HMGA1-mediated regulation but in opposite direction. These results clearly
indicate that HMGA1-mediated gene regulation depends on the cellular
context.
Then, we focused on HMGA1-regulation of Hand1, a transcription factor
crucial for differentiation of trophoblast giant cells and heart development. We
were able to demonstrate that HMGA1 proteins bind directly to Hand1
promoter in vitro and in vivo resulting in the inhibition of the Hand1 promoter
activity. Since the HMGA1 proteins are over-expressed in malignant neoplastic
tissues, we have also investigated Hand1 expression in human thyroid
carcinoma cell lines and tissues: an inverse correlation was found between
HMGA1 and Hand1 expression. Since the down-regulation of the Hand1 gene
expression was not associated neither to loss of heterozygosity nor to alteration
of the methylation pattern, it is reasonable to hypothesize that HMGA1 over-
expression may play a critical role in Hand1 silencing in thyroid carcinomas.
51 BACKGROUND
1.1 HMG superfamily
The high mobility group proteins (HMG) is a superfamily of relatively
abundant and highly conserved nuclear proteins, consisting of 3 families,
HMGA, HMGB and HMGN. HMG families have been grouped based on
similarity in physical and chemical properties and because all act as
architectural elements that affect multiple DNA-dependent processes in the
context of chromatin. In the nucleus, all HMG proteins are highly mobile, bind
transiently to chromatin and compete with histone H1 for nucleosome binding
sites. However, each family is clearly unique, has a characteristic functional
motif, induces specific changes in their binding sites, and performs unique
cellular functions. It is now clear that HMGs impart structural and functional
plasticity to the chromatin fiber; however, their biological function seems
complex and their effects on the cellular phenotype are still not fully
understood.
HMGA proteins interact with a wide range of nuclear components including
transcription factors, components of the splicing machinery, proteins involved
in replication and chromatin assembly factors. HMGA proteins are easily
detectable in cells of early embryos and in undifferentiated or proliferating
cells. In fully differentiated cells their expression is sharply down-regulated
except in malignant and benign tumours (Fedele et al. 2001).
HMGB protein family includes HMGB1, HMGB2 and HMGB3 all of which
are expressed in early embryos. HMGBs were shown to perform important
functions both as intranuclear and as extra cellular regulatory proteins. In the
nucleus, HMGBs are viewed as major architectural components of chromatin
that affect numerous activities including transcription, recombination and DNA
repair. As an extracellular component, HMGB1 affects cell migration and
tumor invasiveness, and also acts as a cytokine that mediates the response to
infection, injury and inflammation (Lotze et al. 2005).
HMGN proteins, which are expressed only in vertebrates, bind specifically
the generic structure of the 147 base pair nucleosome core particle, the building
block of the chromatin fiber. The interaction of HMGN with chromatin reduces
the compaction of the chromatin fiber and affects the rate of transcription,
replication and DNA repair in chromatin templates. By binding to
nucleosomes, HMGNs affect the ability of regulatory molecules and
nucleosome remodeling complexes to reach and modify their chromatin target.
HMGN protein family includes HMGN1, HMGN2, HMGN3, HMGN4 and
NSBP1 which are expressed in a tissue and developmental specific manner
(Shirakawa et al. 2000)
The wide range of cellular activities affected by HMG proteins supports the
general notion that these proteins act as structural components of chromatin but
at the same time raises the question as to which of the various cellular
functions are most affected by these proteins. Indeed, numerous studies suggest
6that HMG proteins also act as specific cofactors in distinct cellular pathways.
For example HMGA1 facilitates the formation of an enhanceosome on the
promoter of the interferon–β gene (Merika and Thanos 2001), HMGB1
stabilizes the binding of the glucocorticoid receptor to chromatin (Bianchi and
Agresti 2005), and HMGN1 is specifically recruited by Cockayne syndrome
protein A to the polymerase stalled at UV-damaged DNA sites (Fousteri et al.
2006).
1.2 HMGA family
HMGA protein family consists of HMGA1 and HMGA2 genes that encode
four proteins named HMGA1a, HMGA1b, HMGA1c and HMGA2, being the
first three proteins spliced forms of the HMGA1 gene. HMGA1 is located at
chromosomal locus 6p21 in humans and in the t-complex locus on
chromosome 17 in mice whereas HMGA2 is located at chromosomal locus
12q14-15 in humans and at the pygmy locus on chromosome 10 in mice.
The HMGA1a, HMGA1b and HMGA2 proteins are composed of 107, 96 and
108 amino acid residues, respectively. Each protein contains three basic
domains, named AT-hooks and an acidic C-terminal region (Figure 1). The
HMGA1a protein differs from HMGA1b in that it has an additional insertion
of 11 amino acid residues between the first and the second AT-hook domains.
The structure of HMGA2 protein is very similar to that of HMGA1b; however,
the first 25 amino acid residues are totally different. Moreover, in HMGA2
there is a short peptide of 12 amino acid residues between the third AT-hook
and the C-terminal acidic tail (Fedele et al. 2001).
Figure 1 Scheme of the sequences of HMGA proteins
7These proteins are very well conserved during evolution, and only a few
differences can be detected between the human and the murine HMGA
sequences. HMGA1c has a deletion of 67 nucleotides compared with the
HMGA1a sequence. This deletion results in a frameshift so that the two
proteins are identical in their first 65 amino acids and differ thereafter. Little is
known about this form that, however, appears to be the only isoform present in
normal human and mouse testis (Fedele et al. 2001).
1.3 Physical and biochemical properties of the HMGA proteins
Originally the HMGA proteins were characterized by their small sizes (10,6-
12 kDa), their solubility in dilute (5%) acids, their unusually high
concentration of basic, acidic and proline aminoacid residues, their highly
phosphorylated state in vivo and their rapid mobility during electrophoretic
separations. Subsequently, HMGA proteins were shown to bind to the minor
groove of short stretches of AT-rich DNA. Given these DNA-binding
properties, it was somewhat surprising when biophysical techniques indicated
that the HMGA proteins, as free molecules, have very little, if any, secondary
structure. HMGA1a protein has relatively little α-helix or β-sheet content and
exhibits greater that 70% random coil or other structural characteristics when
free in solution. Nevertheless, when specifically bound to other molecules,
such as DNA or protein substrates, the HMGA proteins assume induced
structural features. For example, the DNA-binding regions of the HMGA
proteins assume a planar, crescent-shaped configuration called the “AT-hook”
when specifically bound to the minor groove of short stretches of AT-rich
DNA. Each HMGA protein has three similar, but independent, AT-hook
peptides with the consensus sequence of Pro-Arg-Gly-Arg-Pro (with R-G-R-P
being variant) flanked on either side by a number of positively charged
lysine/arginine residues. The core of the AT-hook motif is highly conserved in
evolution from bacteria to humans and is found in one or more copies in a large
number of other, non-HMGA proteins, many of which are transcription factors
or components of chromatin remodeling complexes (Reeves 2001).
HMGA binding can induce structural changes in bound DNA substrates.
Depending on the sequence, the organization, the topology or the length of the
substrate itself, HMGA binding can bend, straighten, unwind and induce
looping in linear DNA molecules. They are also able to introduce supercoils
into relaxed plasmid DNAs in vitro and induce localized changes in the
rotational setting of DNA on the surface of isolated nucleosome core particles.
Interestingly, HMGA proteins also participate in protein-protein interactions
and induce structural changes in the bound protein substrates. One of HMGA
partners is PU.1, a member of the Ets transcription factor family and an
important regulator of the immunoglobulin heavy chain mu (IgGµ) enhancer in
8B-lymphocytes. There is evidence suggesting that the interaction of PU.1 with
HMGA1a induces a structural change in the PU.1 protein that increases its mu
enhancer binding affinity, resulting in an up-regulation of IgGµ gene
transcription. Although the molecular mechanisms that mediate such induced
structural changes in bound proteins are unknown, as with DNA substrates,
they are likely to revolve around the intrinsic disorder and flexibility of the
HMGA proteins (Reeves 2001).
In addition to their other distinguishing characteristics, the HMGA proteins
are among the most extensively modified proteins found in the mammalian
nucleus. A variety of techniques have been employed to demonstrate that the
HMGA proteins are subject to in vivo post-synthetic phosphorylation,
acetylation, methylation and poly-ADP-ribosylation reactions. These
secondary biochemical modifications are dynamic, rapidly responding to both
intra- and extracellular signaling events, and markedly influence both the
substrate-binding properties of the HMGA proteins and their biological
activities.  HMGA proteins undergo phosphorylation by various protein
kinases, including protein kinase C (PKC), cdc2 and casein kinase II. A link
between apoptosis induced in leukaemic cells and the degree of
phosphorylation of HMGA1a protein has been described (Diana et al. 2001).
At the early stages of the apoptotic process, the HMGA1a protein is hyper-
phosphorylated. Subsequently, when the apoptotic bodies are formed, the
HMGA protein becomes almost completely de-phosphorylated.
HMGA proteins are also regulated by acetylation. The transcriptional
coactivator CBP/p300 (CREB-binding protein) and P/CAF (CBP-associated
cofactor) acetylate HMGA1a at distinct lysine residues, causing distinct effects
on transcription.  In the context of the human ß-interferon gene expression,
acetylation of HMGA1a by both CBP and P/CAP is required for the
enhanceosome activation, whereas only CBP acetyltransferase activity is
required for enhanceosome destabilization and post-induction turn-off (Munshi
et al. 1998).
HMGA proteins have the ability to physically interact with a large number of
proteins, most of which are transcription factors: AP-1, ATF-2/c Jun
heterodimer, IRF-1, c-Jun, NF-kB p50/p65 heterodimer, C/EBPß, Elf-1, NF-
AT, NF-kB p50 homodimer, NF-kB p65, NF-Y, Oct-1, Oct-2A, PIAS3, PU.1
RNF4, SRF and Tst-1/Oct-6. Recently, other molecular partners were
discovered using a proteomic approach (Table 1), suggesting an involvement
of HMGA proteins in other chromatin functions, such as RNA-processing,
DNA replication, chromatin structural organization and remodeling. (Sgarra et
al. 2005).
9Table 1   HMGA molecular partners identified by MS analysis
Protein name Accesion number
CBF-beta Q13951
SF3a120 Q15459
hnRNP K Q07244
hnRNP H P31943
hnRNP F P52597
hnRNP MP52272
Ku80 P13010
RBBP-4 Q09028
RBBP-7 Q16576
RuvB-like 2 Q9Y230
Tubulin alpha-1 chain P05209.
Tubulin beta-1 chain P07437
CapZ alpha-1 P52907
NPM P06748
Heat shock cognate 71 kDa protein P11142
GRP 78 P11021
GRWD Q9BQ67
REC14 Q9GZS3
1.4 HMGA proteins and gene transcription
Until 2004 there were reports of over 50 different eukaryotic and viral genes
whose transcriptional expression was regulated by HMGA proteins in vivo
(Table 2). The vast majority (>35) of these are positively regulated and their
inducible expression is controlled by a variety of biological and environmental
stimuli. The promoter regions of many of the positively regulated genes
contain multiple stretches of AT-rich sequence. Transcriptional activation of
these types of promoter often involves the formation of an “enhanceosome”, a
stereo-specific, multi-protein complex that includes HMGA proteins and other
transcription factor making specific protein-DNA and protein-protein contacts
in intricate, but precise, ways. In the case where HMGA proteins act as
negative regulators of gene transcription they often serve as inhibitors of
enhanceosome formation, usually by sterically blocking the functional binding
of other crucial transcription factors to their recognition sites in gene
promoters. (Reeves 2001). Very recently, in our laboratory, we have described
the down-regulation of the recombination activating gene (RAG2) by HMGA1
proteins (Battista et al. 2005).
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Table 2   Genes Regulated by HMGA Proteins
Positive Regulation Negative
Regulation
Vascular Endothelial Tissue CD44 β-Globin
E-Selectin IL-4
IGFBP-1 IgE
iNOS GP 91-phox
COX-2 TCRα
SM22α BRCA1
Immune System MGSA/GROα RAG2
CXCL1
IFN-β
GM-CSF
TNF-β 
IL-2
IL-2Rα
IL-15
HLA-II
c-fos
IgG Heavy Chain
Viral Genes HIV-1 LTR
HSV-1 IE-3
HSV-1 EBNA1
BV EBNA1
VHP 18
JV virus Early & Late Genes
Other Leptin
GATA-1
Hum Insulin Receptor
α-ENaC
Tyrosinase
Rhodopsin
Neurogranin IRC3
PKCγ
mRANTES
Plant Genes Plastocyanin
Nodulin N23 gene
Ferredoxin
Phytochrome A3
Glutamine Synthetase
Soybean hsp17.5E
One of the best-studied mechanisms of gene regulation in which HMGA
proteins are involved is that of the interferon-β gene (IFN- β). The activation
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of the IFN- β expression is due to a multifactor complex that assembles in the
nucleosome-free enhancer region of the gene, formed by the factors NF-kB,
IRF, ATF2/cJun, and the HMGA1a protein (Figure 2). HMGA1a plays a
double function in this context: (i) induces allosteric changes in the DNA, thus
increasing the affinity of the transcription factors for their binding sites and (ii)
establishes protein-protein interactions with the same factors. This new
structure, called enhanceosome, is responsible for the modification and the
remodeling of a nucleosome that masks the TATA-box; consequently,
transcription can start. This remodeling is triggered by the recruitment from the
“enhanceosome” of GCN5/PCAF that acetylates the nucleosome and also
HMGA1a at K64, the latter modification resulting in the stabilization of the
enhanceosome. Later, another acetyltransferase called CBP modifies HMGA1a
at K70 destabilizing the enhanceosome and, consequently, repressing
transcription (Munshi et al. 1998).
Figure 2   HMGA proteins facilitate the assembly of specific multiprotein
complexes required for gene promoter activation
1.5 HMGA expression in normal and neoplastic tissues
The HMGA2 gene is not expressed in any of the several adult mouse and
human tissues tested. A very low expression has been observed in CD34
positive hematopoietic stem cells, and in mouse pre-adipocytic proliferating
cells. The HMGA1 gene is expressed at low levels in adult murine and human
tissues: a higher expression was observed in testis, skeletal muscle ant thymus.
Conversely, both the genes are widely expressed during embryogenesis.
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Hmga1 and Hmga2 over-expression was first described in rat thyroid
transformed cells and in experimental thyroid tumours. Over-expression of the
HMGA proteins was then found to be a common feature of experimental and
human malignant neoplasias, including thyroid, prostate, uterus, breast,
colorectum, ovary and pancreas carcinomas (Fedele et al. 2001). Recently, in
our laboratory, we have correlated HMGA1 expression with the histological
grade of human glial tumors (Donato et al. 2004). Moreover, the expression
level of the HMGA proteins is significantly correlated with parameters of poor
prognosis in patients with colorectal cancer. In all of these
epithelial/endothelial cell-derived malignant tumors, the over-expressed
proteins are full-length non-mutants forms of the HMGA proteins. In contrast
to the situation in carcinomas, benign tumors of mesenchymal origin (lipomas,
leiomyomas, fibroadenomas, aggressive myxomas, pulmonary hamartomas and
endometrial polyps) often contain chromosomal rearrangements that result in
the creation of new hybrid genes that code for chimeric proteins in which the
AT-hooks of the HMGA proteins are fused to ectopic peptidic sequences (Hess
1998).
Over-expression of the HMGA proteins is a necessary event in in vivo cell
transformation. This was demonstrated by experiments in which Hmga
expression was blocked by transfecting rat thyroid cells with antisense Hmga
constructs. When these cells were infected by the myeloproliferative sarcoma
virus and the Kirsten murine sarcoma virus carrying the v-mos and v-ras-Ki
oncogenes, respectively, they did not acquire the typical markers of neoplastic
transformation (ability to grow in soft agar and induce tumors after injection
into athymic mice). Conversely, these markers were shown by the
untransfected rat thyroid cells infected with the same murine retroviruses
(Berlingieri et al. 1995).  Over-expression of HMGA1 proteins is also essential
in the development of cancer in humans. In fact, an adenovirus carrying the
HMGA1 gene in an antisense orientation induces programmed cell death in
carcinoma cell lines derived from human thyroid, lung, colon and breast
cancers (Scala et al. 2000). Moreover, it has been reported that the over-
expression of HMGA1a or HMGA2 leads to neoplastic transformation of both
Rat-1a fibroblasts and CB33 cells, whereas the decrease of HMGA1a/b
expression abrogates transformation in Burkitt’s lymphoma cells (Wood et al.
2000).
1.6 HMGA proteins in embryogenesis and differentiation
In normal cells the expression of HMGA proteins is restricted to
embryogenesis, it decreases with organogenesis and in normal adult cells is
very low or almost absent. In particular, both genes are expressed at high levels
in the entire embryo until 8.5 dpc (Chiappetta et al. 1996, Zhou et al. 1995). At
later stages, the expression pattern becomes more restricted; in particular,
HMGA1 expression is confined to specific body organs of ectodermal,
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mesodermal and endodermal origin, while HMGA2 expression is restricted to
mesenchymal tissues. A role for both factors in development has been
demonstrated: studies carried out by Chada’s group demonstrated that mice
showing a pygmy phenotype carry a disrupted Hmga2  gene and are
characterized by a large reduction of fat tissue and the same group
demonstrated that HMGA1 is required for normal sperm development (Zhou et
al. 1995, Liu et al. 2003). Fusco’s group demonstrated that suppression of
HMGA1 expression impairs differentiation of pre-adipocytic cells and loss of
Hmga1  gene function affects lymphohematopoietic differentiation. We
reported that hmga1-/- ES cells generate less T-cell precursors than do wild
type ES cells upon in vitro specific differentiation. Indeed, they preferentially
differentiate to B-cells, probably consequent to decreased IL-2 expression and
increased IL-6 expression, that are both directly regulated by the HMGA1
proteins. Moreover, a lack of HMGA1 expression results in altered
hemopoietic differentiation, i.e., there is a reduction in the
monocyte/macrophage population, and an increase in megakaryocyte
precursors, erythropoiesis and globin gene expression. Re-expression of the
hmga1 gene in hmga1-/- ES cells restores the wild type phenotype (Battista et
al. 2003). These results indicate that drastic changes occur in the transcriptional
activity of the hmga1-/- cells, and presumably they depend on the modification
of the expression of HMGA1-regulated genes.
1.7 Factors that regulate HMGA gene expression
The structure of the human HMGA1 gene is complex and consists of eight
transcribed exons that produce multiple forms of transcripts as a result of a
complicated pattern of alternative mRNA splicing. Additionally, the gene has
four different promoter/enhancer regions that are capable of independently
initiating transcription depending on the cell type and the nature of the
stimulatory signal. Among these agents that induce HMGA1 gene transcription
are: serum, transforming growth factor α (TGF-α), epidermal growth factor
(EFG), platelet-derived growth factor (PFDG), fibroblast growth factor (FGF),
phorbol esters and calcium ionophores, interferon-β1 (IFN- β1) and endotoxin,
retinoic acid, morphine and hypoxia, as well as the transcription factors AP-1,
c-Myc and the human papillomavirus E6 proteins (Reeves and Beckerbauer
2001). From this partial list of inducing agents it is obvious that many different
signal transduction pathways, and a variety of transcription factors, participate
in the in vivo control of expression of HMGA genes thus paving the way for a
plethora of possible mechanisms that might led to their aberrant regulation and
pathological expression.
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2 AIMS OF THE STUDY
The first aim of the study was to identify new pathways in which HMGA1
proteins are involved.  For this reason, using oligonucleotide microarray
hybridization technique, we analyzed the expression profile of embryonic stem
(ES) cells in which one or both hmga1 alleles were disrupted.  In this way we
could identify the genes that are regulated, positively or negatively, by
HMGA1 proteins.
The second aim of the study was focused on one of the genes identified,
Hand1, a transcription factor crucial for differentiation of trophoblast giant
cells and heart development. We investigated if Hand1-regulation by HMGA1
proteins, could have significance in transformation. For this purpose we
analyzed Hand1 expression in thyroid rat transformed cells, in human thyroid
cell lines and in human thyroid carcinomas.
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3 MATERIALS AND METHODS
3.1 Microarray analysis
Microarray analysis was performed as described in detail at
http://www.cancergenetics.med.ohio-state.edu/microarray. Briefly, cRNA was
prepared from 8 µg of total RNA, hybridized to MG-U74 Affymetrix
oligonucleotide arrays (containing 13,059 murine transcripts), scanned, and
analyzed according to Affymetrix (Santa Clara, CA) protocols. Scanned image
files were visually inspected for artifacts and normalized by using GENECHIP
3.3 software (Affymetrix). Comparisons were made for each mutated sample
versus wild type sample, taking the wild type sample as baseline by using
GENECHIP 3.3. The fold-change values, indicating the relative change in the
expression levels between mutated samples and wild type sample were used to
identify genes differentially expressed between these conditions.
3.2 Plasmids
To study Hand1 promoter, the region  -2424 – -2728 of the mouse Hand1
gene was amplified using as primers gggatacacgaaggtcagtttt (forward) and
ctgagatcccagatcactca (reversed), cloned in TA Cloning Vector (Invitrogen) and
subcloned in pGL3 (Promega) KpnI-XhoI cloning site. The point mutations in
the HMGA binding site of the Hand1 promoter (Hand1MUTprom-luc) were
generated using the QuikChange Mutagenesis Kit (Stratagene) in accordance
with the manufacture’s protocols. The primers used were
t a t t t t a a c t a a t t a G G t a a t a a c a g a g t c t c c t c c t g c c  f o r w a r d )  a n d
ggcaggaggagactctgttattaCCtaattagttaaaata (reversed). Point mutations are
shown in uppercase type. Hand1, HMGA1 and HMGA2 expression plasmids
were constructed by cloning the murine full-length cDNAs of Hand1 or
hmga1b or hmga2 into the mammalian expression vector pcDNA3.1.
3.3 Cell culture and transfections
The generation and the culture of hmga1+/- and hmga1-/- Embryonic Stem
cells are described elsewhere (Battista et al. 2003). FRTL-5, FRTL-5-KiMSV
and FRTL-5–HMGA1as-KiMSV cells, and their culture conditions are
reported elsewhere (Berlingieri et al. 1995). Five x 105 FRTL-5 cells were
plated in 6- well plates and transfected after 48 hours with 1 µg of reporter
plasmid (either Hand1prom-luc, Hand1MUTprom-luc or pGL3), by
Lipofectamine 2000 (Invitrogen). Cells were harvested 24 hours post-
transfection and lysates were analyzed for luciferase activity. Transfection
efficiency was normalized using the β-galactosidase activity and fold of
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activation were calculated by dividing for pGL3 luciferase activity. All the
assays were performed in triplicate and repeated in three independent
experiments.
Human thyroid primary culture and human thyroid carcinoma cell lines
(TPC-1, WRO, NPA, ARO, FRO, NIM 1, B-CPAP, FB-1, FB-2, Kat-4 and
Kat-18) are described elsewhere (Pallante et al. 2005).
3.4 Tissue samples
Neoplastic human thyroid tissues and normal adjacent tissue or the
controlateral normal thyroid lobe were obtained from surgical specimens and
immediately frozen in liquid nitrogen. Thyroid tumours were collected at the
Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Benite,
France. The tumour samples were stored frozen until RNA extractions were
performed. Tissues from hmga1 +/- and hmga1 -/- mice have been described
elsewhere (Martinez Hoyos et al. 2004).
3.5 RNA extraction from tissues and cells
Tissues were snap-frozen in liquid nitrogen and stored at –80°C until use.
Total RNAs were extracted from tissues and cell culture using TRI
REAGENT® (Molecular Research Center INC) solution, according to the
manufacture’s instructions. The integrity of the RNA was assessed by
denaturing agarose gel electrophoresis (virtual presence of sharp 28S and 18S
bands) and spectrophotometry.
3.6 Semiquantitative and quantitative RT-PCR
RNAs were treated with DnaseI (Invitrogen) and reverse-transcribed using
random exonucleotides as primers and MuLV reverse transcriptase (Perkin
Elmer). To ensure that RNA samples were not contaminated with DNA,
negative controls were obtained by performing the PCR on samples that were
not reversed-transcribed but otherwise identically processed. For
semiquantitative PCR, reactions were optimized for the number of cycles to
ensure product intensity within the linear phase of amplification. The PCR
products were separated on a 2% agarose gel, stained with ethidium bromide
and scanned using a Typhoon 9200 scanner. Digitized data were analyzed
using Imagequant (Molecular Dynamics). Quantitative PCR was performed
with SYBR® Green PCR Master Mix (Applied Biosystems) as follows: 95 °C
10 min and 40 cycles (95 °C 15 s  and 60 °C 1 min). Each reaction was
performed in duplicate. To calculate the relative expression levels we used the
2-DDCT method (Livak et al. 2001). The primers sequences are: murine F
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gatgccttctcgagttaaaa and R aagtgtagcgacaagaagga, rat F gttcaggacccaaaaagg
and R gcagagtcttgatcttggag, human F ctggctctttctctcttgtc and R
cgtctggttctctttctcag.
3.7 Protein Extraction, Western Blotting and Antibodies
Tissues and cell culture were lysed in buffer 1% NP40, 1mM EDTA, 50mM
Tris-HCl pH 7.5, 150 mM NaCl, supplemented with CompleteTM protease
inhibitors cocktail (Roche Diagnostic Corp.). Total proteins were separated by
SDS-PAGE and transferred to nitrocellulose membranes (Biorad). Membranes
were blocked with 5% nonfat milk and incubated with antibodies against
Hand1 and Tubulin. Hand1 antibody was a generous gift from Dr. Peter
Cserjesi (New Orleans, USA). Bound antibody was detected by anti-guinea pig
secondary antibody and revealed with an enhanced chemiluminescence system
(Amersham-Pharmacia Biotech).
3.8 Electrophoretic Mobility Shift Assay
The production of recombinant proteins was previously described
(Baldassarre et al. 2003). Five or 20 ng of recombinant protein were incubated
with radiolabeled double-strand oligonucleotides, corresponding to the region
spanning bases  -2658 to -2688 of the 5’ untranslated region of the murine
Hand1 promoter  (5’- atttattttattttaactaattaattaataa-3’). A 200-fold excess of
specific unlabeled competitor oligonucleotide was added. The same
oligonucleotides were also used in binding assays with total extract from wild
type and hmga1-knockout murine ES cells. 8 µg of extracts were incubated in
20 mM Hepes pH 7.6, 40 mM KCl, 0.1 mM EDTA, 0.5 mM MgCl2, 0.5 mM
DTT, 0.1 mM PMSF in a volume of 20 µl containing 1 µg of poly(dC-dG), 2
µg BSA and 10% glycerol, for 10 min at room temperature. Binding reactions
were incubated for 10 min after addition of 2.5 fmol of 32P-end labeled
oligonucleotides (specific activity, 8,000 to 20,000 cpm/fmol). The DNA-
protein complexes were resolved on 6% non-denaturing acrylamide gels and
visualized by exposure to autoradiographic films.
3.9 Chromatin immunoprecipitation
Approximately 3x107 wild type, hmga1 +/- and -/- ES cells were grown on
75 cm2 dishes. Chromatin immunoprecipitation was performed as previously
described (Martinez Hoyos et al. 2004). Input and immunoprecipitated DNA
were analyzed by PCR for the presence of Hand1 promoter sequence spanning
–2424 to -2927. The primers used were 5'- cttggtgacaagcacctt-3’ (forward) and
5'- ctgagatcccagatcactca-3’ (reverse).
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3.10 Methylation analysis using bisulphite genomic sequencing
The promoter region of human HAND1 gene was analyzed for CG content; a
CpG island was determined based on a 200-bp lenght of DNA with a CG
content of >50% and a CpG/GpC ratio of >0.5, using CpGplot program,
available at http://www.ebi.ac.uk/emboss/cpgplot/. Bisulphite genomic
sequencing was used to analyze the methylation patterns of individual DNA
molecules. Sodium bisulphite conversion of genomic DNA (about 200 ng for
each conversion) was obtained using EZ DNA Methylation Kit (ZYMO
Research) following the manufacturer's instructions. The CpG islands
identified as described previously were then PCR amplified using the
following primers: Pre-Nested PCR 3FHand (-461 to -430)
gtagagtagttggagttygggattgggaattg,  3RHand (+180 to +211)
ctccatacrccccaaaaactaccraaaaccac. Nested PCR 3FnHand (- 275 to -249)
ggagggggtggtagtaa tagt t taggg,  3RnHand (+170 to  +201)
ccccaaaaactaccraaaaccacctataaactc. PCR reactions were carried out using
FastStart Taq DNA polymerase (Roche) under the following conditions: 1)
Pre-nested PCRs were normally carried out on 10 ng of bisulphite treated DNA
in a final reaction volume of 50 ml, using standard conditions with 1,5 min at
95°C, followed by 5 cycles of  30 sec at 95°C, 30 sec at 59°C, and 40 sec at
72°C,  then 25 cycles of 30 sec at 95°C, 30 sec at 57°C, and 40 sec at 72°C,
then a final elongation of 6 min at 72°C before holding at 4°C. 2) Nested PCRs
were performed in the same conditions, using 5 ml of the corresponding pre-
nested PCRs in a final reaction volume of 50 ml. PCR final products (477 bp)
were then cloned into the pGEM-Teasy vector provided by Promega pGEM-T
Easy Vector System II, following the supplier’s procedures. The positive
screened colonies contained the unique sequence of one individual DNA
molecule. The plasmidic DNA from the selected positive colonies containing
vectors with the insert was purified using the Qiagen plasmid Mini Kit. The
purified plasmids were sequenced in both directions using T7 and Sp6 primers.
20 independent clones for each genomic preparation and fragment of interest
were sequenced to determine the methylation pattern of individual molecules.
Sequencing was performed at the CEINGE Sequencing Core Facility.
3.11 SNP-based Loss of Heterozygosity analysis
We performed LOH analysis using Single Nucleotide Polymorphisms. To
identify the SNPs scattered in the genetic locus of HAND1, we input HAND1
human gene name in the SNP database of NCBI and we found eight SNPs. The
primers, SNP reference and alleles are: F- cgaaataggcaaacaggctc and R-
aaagctcatccagggacga for rs924581 (A/G); F- gaagacccgatctgttttacct and R-
cttcaaggctgaactcaagaa for rs4370323 (A/G), rs1846966 (C/G), rs11748765
(A/T); F- cgctgttaatgctctcagt and R- gtaaaacctgggatagcca for rs6880185 (A/G),
rs13171812 (C/T), rs993098 (A/C), rs3822714 (A/G). The primers used for
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PCR was also used for sequencing assays. PCR was performed using
HotMaster Taq DNA Polimerase (Eppendorf AG, Germany) in a final volume
of 25 µl. For amplification reaction we used 50 ng of genomic DNA, 0,5 unit
of Hotmaster Taq DNA polymerase, a final concentration of each primer of 0.2
µM and 0.2mM of dNTPs and 2,5 µl of 10x HotMaster Taq DNA Polimerase
Buffer with Mg2+. The conditions used for PCR was a initial denaturation at
94°C for 2 min, 35 cycles of 94°C for 20 sec, 58°C for 10 sec, 70°C for 40 sec
and a final extension of 5 min at 70°C. After amplification the size and quality
of amplicons was checked loading 5 µl of reactions on agarose gel. 20 µl of
each PCR was sequenced with specific forward and reverse primers used for
amplification reaction.
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4 RESULTS AND DISCUSSION
4.1 Gene expression profile analysis
RNAs extracted from wild type, hmga1+/- and hmga1-/- ES cells were
hybridized to MG-U74 Affymetrix oligonucleotide arrays containing 13,059
transcripts. The expression profile of the heterozygous and homozygous ES
cells was compared to that of the wild type ES cells that was used as a common
reference. The number of transcripts increased or decreased in the
heterozygous and the homozygous mutant versus wild type sample is shown in
the Figure 3. Of the 13,059 transcripts represented on the array, 1,300 had a
fold-change between two and three, 313 between three and four, 227 between
four and ten, and 23 greater than ten. We examined the 250 transcripts (1.9%)
that had a fold-change of four or more in the homozygous mutant versus the
wild type sample. Among these 250 transcripts, 87 were increased and 163
were decreased, including 103 known genes (37 increased and 66 decreased),
118 ESTs (40 increased and 78 decreased), and 29 unknown genes (10
increased and 19 decreased). As a control of microarray analysis, we verified
that the HMGA1 was not expressed in hmga1-/- ES cells. The genes with fold-
change of four or greater in hmga1-/- ES cells were grouped according to their
function: a) signal-transduction pathways, b) transcription factors, c) cell
proliferation, d) extracellular-matrix and cellular-structure proteins, e)
metabolic pathways, transport and secretion, f) growth factors and related
proteins, g) genes with immune functions and h) other genes. The relative fold-
changes in these genes, grouped as described above, are shown in Table 3. It is
noteworthy that among the HMGA1-regulated genes we found Id3, lefty and
Wnt-6 that are important in embryonic development and some oncogenes such
as c-myc, junB, pim-2 and c-fos.
Figure 3   Gene expression profile in ES cells carrying one or two hmga1-
disrupted alleles
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4.2 Validation of microarray analysis
To validate the results obtained by microarray analysis we evaluated the
expression of 50 transcripts by semiquantitative and quantitative RT-PCR in the
wild type, hmga1+/- and hmga1-/- ES cells.  For all of them, the differential
expression associated with the expression of the HMGA1 proteins was
confirmed.  Some representative semiquantitative RT-PCR analysis are shown
in Figure 4. The expression of some genes, i.e., TFEB, LKLF, and Id3 was
Hmga1 dose-dependent. In fact, the changes in hmga1+/- ES cells were
intermediate between those found in wild type and hmga1-/- ES cells.
Conversely, the expression of other genes, i.e., cubilin, p96, D-9K, legumain
and collagen was not modified in hmga1+/- ES cells in comparison to the wild
type ES cells.
Figure 4   Validation of microarray data by semiquantitative RT-PCR
Thus, for some genes the level of hmga1 expression may be critical for
appropriate gene expression. In this case both alleles seem to be necessary to
regulate the expression of these genes. For some other genes, the dependency on
the hmga1 expression levels was even more pronounced since the gene
expression level in heterozygous ES cells was very close to that observed in
homozygous cells. This type of regulation by hmga1 expression levels may
explain the appearance of pathologies, such as cardiac hypertrophy and B cell
lymphomas, in mice heterozygous for hmga1 gene disruption (Fedele et al,
2006).  Several other genes showed the same expression level in wild type and
heterozygous ES cells. In this case one hmga1 allele is sufficient to regulate
gene expression.
cubilin
p96 Collagen pro-α1 type I
TFEB
Cts H H19LKLF
Id3
legumain cyclin D1zif268
D-9k β-actinVsm Actin
mh23d10.r1
gly96 SM22 mi45g01.r1
+/+ +/- -/- +/+ +/- -/- +/+ +/- -/-
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Table 3   The genes differentially expressed with a fold-change of 4 or higher in
homozygous (-/-) hmga1-knockout ES cells grouped in families. Acc.No. = accession
number; FC = fold change
DESCRIPTION Acc. No. FC   +/- FC  -/-
A. Signal transduction
M. musculus parathyroid hormone/parathyroid hormone related-peptide receptor L34611 1.1 18.4
M.musculus mRNA for ryudocan core protein D89571 3.9 10.6
M.musculus mitogen-responsive 96 kDa phosphoprotein p96 U18869 1.7 9.3
M. musculus mRNA for MAP kinase-activated protein kinase 2 BC063064 10 4.7
Mouse Wnt-6 M89800 1.1 4.1
M.musculus JIP-1 AF003115 -1.7 -4
Murine macrophage gene, encoding bmk (B cell/myeloid kinase) J03023 -1.4 -4.1
M.musculus TGF-beta-inducible protein (TSC-36) M91380 1.3 -4.2
M.musculus mRNA for retinoic acid receptor-alpha X57528 1.1 -4.3
Mouse growth factor-inducible protein (pip92) M59821 -2.5 -4.4
Mouse oxytocin-neurophysin I M88355 1.7 -4.5
M.musculus patched U46155 -1.2 -4.6
Mouse G protein alpha subunit (GNA-15) M80632 -9.4 -4.7
Mouse mRNA for NBL4 D28818 -2.1 -5.1
M.musculus receptor protein tyrosine phosphatase-lamda (ptp-lambda) U55057 1.3 -5.4
M.musculus protein-serine/threonine kinase (pim-2) L41495 -1.7 -5.6
Mouse (clone M1) GTPase (Ran) L32751 2.6 -5.7
M.musculus ShcC U46854 1.3 -6.3
M.musculus syk mRNA for protein-tyrosine kinase Z49877 -1.3 -6.3
M.musculus c-Src kinase (Csk) U05247 -1.6 -8.6
B. Transcription factors
M.musculus Thing1 U21226 3.8 14
M. musculus  adult testis mRNA for truncated form of Sox17 D49473 1.3 13.7
M.musculus melanocyte-specific gene 1 (msg1) U65091 1.4 9.7
M.musculus mRNA for fos-related antigen-2 X83971 3.1 4
M.musculus Sox4 (Sox4) ET62444 -1.4 -4.1
Mouse c-fos oncogene V00727 -12 -4.2
Mouse c-myc L00039 -4.3 -4.3
M.musculus AP-2.2 X94694 -1.6 -4.4
Mouse mRNA for Zfp-57 D21850 -2.5 -4.6
M.musculus Kruppel-like factor LKLF U25096 -1.4 -4.8
M.musculus transcription factor TFEB U36393 -2.2 -4.9
M.musculus transcription factor NF-YC subunit U62297 -2.6 -5.2
M.musculus DNA binding protein NFI-X (NfiX) U57636 -1.9 -6.2
M. musculus mRNA for TIF1 beta protein X99644 -5.8 -6.2
M.musculus transcription factor junB U20735 -3.5 -6.4
M. musculus Oct-6 mRNA for octamer binding protein X57482 -8.1 -6.5
Mouse helix-loop-helix protein (Id related) M60523 -5.3 -7.4
Mouse growth factor-induced protein (zif/268) M22326 -8.2 -24.9
C. Cell proliferation
M. musculus chop-10 X67083 15.1 16.9
Mouse D-type cyclin (CYL2) M83749 -2.5 9
M. musculus gly96 X67644 4.4 8
M.musculus mRNA for zyxin Y07711 1.3 5.3
D. Extracellular-matrix and cellular-structure
M.musculus laminin A chain J04064 1.2 14
M.musculus alpha-2 type IV collagen J04695 1.4 9.8
M.musculus alpha-1 type IV collagen (Col4a-1) J04694 1.4 9.1
Mouse alpha-B2-crystallin M73741 1.4 7.7
Mouse laminin B1 M15525 1.3 6.3
Mouse mRNA for cysteine-rich glycoprotein SPARC NM_009242 1.2 5.5
Mouse gelsolin J04953 1.5 4.5
M.musculus mRNA for hair keratin, mHb6 X99143 3.5 4.1
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Mouse alpha-B crystallin M63170 1 4
Mouse COL1A2 mRNA for pro-alpha-2(I) collagen X58251 -3.8 -4.1
M.musculus rhoB X99963 -7.4 -4.2
M.musculus neurofibromatosis 2 (Nf-2) L27090 1.3 -4.5
M.musculus SM22 alpha L41154 -1.5 -4.5
Mouse COL1A2 mRNA for pro-alpha-2 (I) collagen NM_007743 -3.9 -4.7
M.musculus alpha 1 type I collagen U50767 -1.9 -5.6
M.musculus mRNA for myosin I X97650 -4.6 -6.3
Mouse tau microtubule binding protein M18776 -1.3 -6.6
M.musculus FVB/N collagen pro-alpha-1 type I chain U08020 -2.1 -7.5
Mouse mRNA for vascular smooth muscle alpha-actin X13297 -2.1 -8.6
E. Metabolism, transport and secretion
Mouse mRNA for mastocytoma proteoglycan core protein, serglycin. X16133 2.6 40.9
M.musculus cathepsin H prepropeptide (ctsH) U06119 1.5 17.3
M.musculus calcium binding protein D-9k AF028071 2.3 9.8
Mouse serine protease inhibitor homologue (J6) J05609 1.7 8.7
M. musculus heparan sulfate D-glucosaminyl 3-O-sulfotransferase-1 precursor AF019385 -1.4 6.5
Mouse mRNA for preproinsulin-like growth factor IA X04480 -1.5 6.2
M.musculus preprodipeptidyl peptidase I U89269 1.2 5.9
M.musculus mRNA for cytoplasmic dynein heavy chain ET63396 1.6 5.5
M.musculus steroid cytochrome p450 7-alpha hydroxylase L06463 -1.1 -4
M.musculus very-long-chain acyl-CoA synthetase (VLCS) AF033031 -2 -4
M. musculus (N-acetylglucosaminyltransferase I L07037 2.5 -4.1
Mouse mRNA for inward rectifier K+ channel D50581 1 -4.1
M.musculus preprocortistatin (Cort) AF013253 2.7 -4.3
M.musculus extracellular superoxide dismutase (SOD3) U38261 1.2 -4.6
Mouse mRNA for a preprothyrotropin-releasing hormone X59387 -1.1 -4.7
M.musculus steroid sulfatase (Sts) U37545 -2.3 -4.7
M.musculus mRNA for dihydropyrimidinase related protein 4 AB006715 5.7 -4.9
M. musculus putative chloride channel protein CLC6 (Clc6) AF030106 -1 -4.9
Mouse placental alkaline phospatase J02980 -1.1 -4.9
M.musculus Balb/c cytochrome c oxidase subunit VIaH U08439 3.1 -5
Mouse metallothionein-III M93310 1.4 -5.3
M.musculus carboxypeptidase E (Cpe) U23184 -3.5 -5.8
M.musculus hormone-sensitive lipase U08188 -1.7 -8
M.musculus ADP-ribosylation factor-like protein 4 U76546 -2.4 -8.7
F. Growth factors and related proteins
M.musculus lefty AJ000083 -1.1 -4.3
M.musculus mRNA for insulin-like growth factor binding protein-3 X81581 -3.2 -6.4
M.musculus mRNA for insulin-like growth factor binding protein-4 X81582 -1.4 -7.3
M.musculus acid labile subunit (ALS) U66900 2.4 -7.4
Mouse Cyr61 M32490 -4.2 -8.4
M.musculus follistatin-like protein (mac25) L75822 -2.6 -11
G. Immune functions
Mouse gene for 47-kDa heat shock protein (HSP47) D12907 1.1 5.7
M.musculus MHC class I B(2)-microglobulin M84366 1.2 5
Mouse lymphocyte differentiation antigen (Ly-6.2) M18184 1.7 4.9
M. musculus anti-digoxin immunoglobulin heavy chain variable region precursor ET62206 2 4.7
Mouse CD19 M62553 3.3 -4.1
M.musculus (clone B6) myeloid secondary granule protein L37297 -2 -4.3
M.musculus putative TNF-resistance related protein U90926 -1.5 -6.5
Mouse mRNA for poliovirus receptor homolog protein soluble form D26107 -3.7 -12.2
H. Other functions
Mouse surfeit locus surfeit 3 protein M14689 3.3 4.5
Mouse ERA-1-993 M22115 3.3 4.1
M.musculus imprinted in placenta and liver (Ipl) AF002708 -1.7 -4.1
M.musculus H19 X58196 2.6 -5.9
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4.3 Some of the genes differentially expressed in hmga1–knockout ES
cells depend on Hmga1 expression also in other cells and tissues
We next verified whether the genes differentially expressed in hmga1-
knockout ES cells showed a differential expression also in embryonic
fibroblasts isolated from hmga1-knockout mice. A semiquantitative RT-PCR
analysis showed that the differential expression of some genes, i.e., D-9k, gly
96 and LKLF in hmga1-/- fibroblasts matched that found in hmga1-knockout
ES cells, whereas the expression of other genes did not (Figure 5). We next
evaluated the expression of the HMGA1-regulated genes in adult heart, liver
and spleen tissue from hmga1 +/- and hmga1 -/- knockout mice.
Some genes, such as Id3 and p96 showed the same expression trend as in ES
cells, being down-regulated and up-regulated by HMGA1, respectively, also in
heart and spleen. Some other genes only changed in one type of tissue, for
example, gly96 and LKLF expression was different only in spleen, TFEB and
Laminin α1 only in heart. Interestingly, the regulation of some genes, such as
TFEB and Laminin α1, in adult tissues was opposite to that found in ES cells.
In fact, they were decreased in ES cells but increased in heart. These results
suggest that HMGA1 function depends on the cellular context.
Figure 5   Gene expression in hmga1-knockout cells and tissues
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p96
Laminin α1
SM22
TGF-β1
D-9k
GATA4
zif268
Id3
gly96
LKLF
c-fos
MEF HEART SPLEEN LIVER
+/+   +/-   -/- +/+   +/-   -/- +/+   +/-   -/- +/+   +/-   -/-
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 It is known that by interacting with partner proteins, the HMGA1 proteins are
able to enhance or suppress the effect of more “traditional” transcriptional
activators and repressors. The fact that partner proteins are critical for HMGA1
activity, may account for the cell- and tissue- specific regulation exerted by the
HMGA1 proteins.
4.4 Analysis of the HMGA1-dependent genes in transformed cells
We previously demonstrated that HMGA1 over-expression is a necessary
event in cell transformation. In fact, when HMGA1 expression was blocked by
transfecting rat thyroid cells (FRTL-5) with an antisense hmga1 cDNA
construct and infected with the Kirsten murine sarcoma virus (KiMSV) carrying
the v-ras-Ki oncogene, they (FRTL-5-HMGA1as-KiMSV) did not acquire the
typical markers of neoplastic transformation (ability to grow in soft agar and
induce tumors after injection into athymic mice), even though the differentiation
markers (i.e., TSH-dependency, ability to trap iodide, thyroglobulin synthesis
and secretion) were lost. Conversely, the neoplastic markers were shown by the
untransfected rat thyroid cells infected with the same murine retrovirus (FRTL-
5-KiMSV). Therefore, as shown in Figure 6, we analyzed, by RT-PCR, the
expression of some hmga1-dependent genes in FRTL-5 (lane 1), FRTL-5-
KiMSV (lane 2) and FRTL-5-HMGA1as-KiMSV (lane 3) cells.  The
experiments revealed two sets of genes. Some genes showed the same
regulation observed in the ES cells i.e., Carboxipeptidase E (Cpe) that decreased
in hmga1-knockout ES cells and increased in the neoplastic cells or cathepsin H
(ctsH) that increased in hmga1-knockout ES cells and decreased in the
neoplastic cells compared to the wild type controls. Other genes were regulated
in an opposite direction compared to ES cells, i.e., p96 and mac25 which
demonstrated an increased and a decreased level, respectively, in both hmga1-
knockout ES and FRTL5 KiMSV cells, compared to the respective controls,
despite the fact that the HMGA1 proteins were expressed only in the latter cells.
Figure 6  Gene expression in  transformed cells over-expressing HMGA1
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4.5 HMGA1 proteins bind to id3 and p96 promoters
The differential gene expression depending on the HMGA1 presence could
depend on an indirect effect of the HMGA1 proteins in the sense that HMGA1
might induce some proteins which may interfere with the expression of some
genes. To exclude this possibility and demonstrate a direct effect of HMGA1
on the regulation of some genes differentially expressed in hmga1-knockout
cells, we performed EMSA and chromatin immunoprecipitation experiments.
We examined the Id3 and p96 genes because they were modified at RNA
level in different cells and tissues and because their promoter regions contain
AT-rich sequences that are a preferential binding site for the HMGA proteins.
To investigate whether the HMGA1 proteins were able to bind the AT-rich
promoter regions of both Id3 and p96, we performed an electrophoretic
mobility shift assay (EMSA) using oligonucleotides spanning nucleotides -632
to -615 of the murine Id3 promoter region and -901 to -872 of the 5’
untranslated region of the murine p96 gene. As shown in Figure 7, a
recombinant HMGA1 protein was able to bind directly to these regions.
Binding specificity was demonstrated by competition experiments showing
loss of binding with the addition of 200-fold molar excess of a specific,
unlabeled oligonucleotide.  Subsequently, we performed binding assays with
total extract from wild type and hmga1-knockout murine spleens. Two specific
complexes with a mobility corresponding to the HMGA1 proteins (isoforms
A1a and A1b) were present in extracts from wild type and heterozygous (data
not shown) spleens, while they were absent in extracts from homozygous
hmga1-knockout mice. These complexes were specifically displaced by the
incubation with an antibody directed against the HMGA1 proteins
demonstrating that these complexes do consist of the HMGA1 proteins. A
control gel shift  for Sp1 was performed to normalize the spleen extracts used
(Panel C).
To verify that  HMGA1 proteins bind to  Id3 and p96 promoters in vivo we
performed experiments of chromatin immunoprecipitation in MEF from wild
type and hmga1-knockout mice. Chromatin prepared as described under
“Materials and Methods” was immunoprecipitated with anti-HMGA1 or
normal rabbit IgG antibodies. The results shown in Figure 7D demonstrate that
HMGA1 proteins bind to these promoters. In fact, the Id3 and p96 promoter
regions were amplified from the DNA recovered with anti-HMGA1 antibody
in wild type and hmga1+/- but not in hmga1-/- MEFs. Moreover, no
amplification was observed in samples immunoprecipitated with normal rabbit
IgG.
 We retain of particular interest the finding that p96 and Id3 are regulated by
the HMGA1 proteins since they are believed to have a critical role in the
process of carcinogenesis. In fact, even though no putative alterations on Id
genes have identified in primary human tumours to date to certify Ids as true
cellular proto-oncogenes, Id proteins, that are basic helix-loop-helix
transcription factors, have been implicated in regulating a variety of cellular
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processes, such as cellular growth, senescence, differentiation, apoptosis,
angiogenesis, that regulate tumorigenesis (Sikder et al. 2003). In particular Id3
has been frequently found increased in human neoplasias. Equally, p96, a
mitogen-responsive phosphoprotein cloned from a mouse macrophage cell
expression library, is consistently down-regulated in mouse mammary
carcinogenesis and in human ovarian carcinomas as compared to normal
surface epithelium (Schwahn and Medina 1998, Mok et al. 1998). It is likely
that Id3 up-regulation and p96 down-regulation in human neoplasias depends
also on the HMGA1 over-expression, a feature of most of the human malignant
neoplasias (Fedele et al. 2001).
Figure 7 HMGA1 proteins bind Id3 and p96 promoters in vitro and in vivo.
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4.6 Loss of HMGA1 correlates with an increased Hand1 expression in
murine ES cells, heart and thyroid tissues
Microarray analysis of the expression profile of embryonic stem (ES) cells
bearing one or two disrupted hmga1 alleles revealed the Hand1 gene as a gene
likely negatively regulated by HMGA1. In fact, the chip showed a 3,8 fold-
change for heterozygous cells and a 14 fold-change for homozygous cells
(Martinez Hoyos et al. 2004). Therefore, our first aim was to validate the
results obtained by microarray analysis by semiquantitative and quantitative
RT-PCR (Figure 8A and 8B). These analyses confirmed the differential
expression between wild type and hmga1-knockout ES cells. They clearly
showed that regulation of Hand1 expression was HMGA1-dose dependent
since an intermediate level of Hand1  expression was observed in the
heterozygous ES cells.
 The analysis of the Hand1 expression in heart and thyroid tissues derived
from hmga1-knockout mice revealed the same kind of regulation by HMGA1
(Figure 8C). Conversely, no changes in Hand1 expression were observed
depending on the Hmga1 expression when embryonic fibroblasts, brain,
spleen, liver, kidney, pancreas and thymus from hmga1 minus mice were
analyzed (data not shown). This confirmed that HMGA1-mediated gene
regulation depends on the cellular context. Interestingly, when we analyzed
same tissues from the Hmga2 minus mice, no changes in Hand1 expression
were observed indicating that Hand1 regulation was HMGA1 specific.
Figure 8   Hand1 expression in hmga1 knockout cells and tissues
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4.7 HMGA1 proteins bind to murine Hand1 promoter
To evaluate whether the differential gene expression was a direct effect of
HMGA1 we performed an electrophoretic mobility shift assay (EMSA). In
particular, we analyzed a region spanning nucleotides -2658 to -2688 of the 5’
untranslated region of the murine Hand1 gene containing AT-rich putative
HMGA1 binding sites. As shown in Figure 9A, a recombinant HMGA1 protein
was able to bind directly to this region. Binding specificity was demonstrated
by competition experiments showing loss of binding with the addition of 200-
fold molar excess of specific, unlabeled oligonucleotides. Subsequently, we
performed binding assays with total extract from wild type and hmga1-
knockout ES cells. A specific complex with a mobility corresponding to the
HMGA1 proteins was present in extracts from wild type while it was absent in
extracts from homozygous hmga1-knockout ES cells (Figure 9B). To verify
that  HMGA1 proteins bind to  Hand1  promoter in vivo we performed
experiments of chromatin immunoprecipitation. Anti-HMGA1 antibodies
precipitated Hand1 promoter from hmga1 +/+ and +/- ES cells, but not from
hmga1 -/- ES cells (Figure 9C).
Figure 9   HMGA1 binding to Hand1 upstream regulating region
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4.8 HMGA1 proteins repress the murine Hand1 promoter
In order to investigate the functional effect of HMGA1 proteins on Hand1
promoter, we transiently transfected the rat thyroid cells, FRTL-5, that express
low levels of HMGA1 with a construct expressing the luciferase gene under
the control of the mouse Hand1 promoter region -2424 – -2728. As shown in
Figure 10A, when the HMGA1 expression vector was transfected, a reduction
of the luciferase activity was observed in a dose-dependent manner.  No
decrease in Hand1 promoter activity was obtained when the cells were
transfected with a construct expressing HMGA2 the other member of the
HMGA family. Then, we generated two point mutations in the putative binding
site for the HMGA1 protein replacing adenine -2681 and thymidine -2682 with
two guanines. Over-expression of HMGA1 was able to reduce the activity of
the wild type construct but it completely failed in its inhibitory effect if the
HMGA1 binding site of this construct was mutated (Figure 10B).
Figure 10   Repression of Hand1 promoter activity by HMGA1 proteins
4.9 Hand1 expression is decreased in thyroid cell transformation
The HMGA1 proteins are over-expressed in several malignant neoplasias.
Then, in order to evaluate a possible role of Hand1 regulation by HMGA1 in
cell transformation, we analyzed, by RT-PCR, the expression of Hand1 in
FRTL-5 normal thyroid cells which do not express significant levels of
HMGA1, in the same cells transformed by the Kirsten murine sarcoma virus,
which express high levels of HMGA1 (FRTL-5 –KiMSV) and in the FRTL-5
cells which have been transfected with an hmga1 antisense construct before
being infected by Ki-MSV (FRTL-5-HMGA1as-KiMSV cells), and that do not
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express the HMGA1 proteins. A significant Hand1 expression was observed in
the cells which do not express the HMGA1 proteins, such as the FRTL-5 and
FRTL-5-HMGA1as-KiMSV, whereas no expression was observed in the
FRTL-KiMSV cells expressing high levels of HMGA1 proteins (Figure 11A).
These results confirm an inverse correlation between HMGA1 and Hand1
expression also in transformed cells.
Subsequently, we analyzed the expression of HMGA1 and Hand1 in a panel
of thirteen human thyroid carcinoma-derived cell lines. An inverse correlation
between HMGA1 and Hand1 expression levels was observed. In fact, HMGA1
expression was increased in all tumor-derived cell lines tested when compared
to normal primary cultured cells used as a control (Figure 11B); conversely,
HAND1 mRNA expression level was much lower in all of the thyroid
carcinoma cell lines compared to normal cells (Figure 11B).
Finally, Hand1 and HMGA1 gene expression was examined in 20 surgically
removed human thyroid carcinomas by real time PCR (Figure 11C). Again, an
inverse correlation between HMGA1 and Hand1 mRNA levels was observed.
In fact, HMGA1 mRNA levels were almost undetectable in normal thyroid
tissue, whereas they were highly expressed in most of the tumors analyzed. In
contrast, Hand1 expression was strongly diminished in all tumor samples
compared to normal thyroid tissue.
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Figure 11   Hand1 expression in thyroid tumorigenesis. (A) Hand1 expression in
transformed rat thyroid cells over-expressing HMGA1 by semiquantitative RT-PCR.
Sources of RNA are FRTL-5, rat thyroid epithelial cell line (lane 1); FRTL-5-KiMSV,
FRTL-5 infected with the Kirsten murine sarcoma virus (lane 2); FRTL-5-HMGA1as-
KiMSV, FRTL-5 transfected with a construct carrying HMGA1 mRNA in an antisense
orientation, and then infected with the Kirsten murine sarcoma virus (lane 3). (B)
Hand1 expression in human thyroid carcinoma cell lines by semiquantitative RT-PCR
(C) human thyroid tumors by  real- time PCR.
4.10 Down-regulation of HAND1 expression in human thyroid
carcinomas is not associated to LOH and DNA methylation
We have analyzed the methylation status of three thyroid carcinoma samples
showing the lowest HAND1 expression and normal thyroid. We have analyzed
the region of the 5’ untranslated region of the human HAND1 gene, described
under Materials and Methods. This region was unmethylated in normal and
carcinoma samples indicating that the silencing of Hand1 gene in neoplastic
samples is not dependent on the gene promoter hypermethylation.
Therefore, we analyzed the same three thyroid carcinoma samples for Loss of
Heterozygosity (LOH). We analyzed eight Single Nucleotide Polymorphisms:
however no LOH was found.
Therefore, these results would suggest that it is likely that the HMGA1-
negative regulation plays a critical role in Hand1 gene suppression in human
thyroid carcinomas.
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4.11 Restoration of Hand1 gene expression inhibits the growth of thyroid
carcinoma cell lines
To determine whether loss of Hand1 gene expression affects thyroid
carcinogenesis, we evaluated the growth rate of thyroid carcinoma cell lines in
which Hand1 expression had been restored. To this aim we carried out a
colony forming assay with a cell line obtained from human thyroid carcinomas
(FB-2) after transfection with the vector carrying the Hand1 gene or the empty
backbone vector. The colonies were scored after two weeks. Cells transfected
with the Hand1  gene generated a lower number of colonies than cells
transfected with the backbone vector (Figure 12).
Figure 12 Restoration of Hand1 gene expression reduces clonogenic capacities of
thyroid cancer cells.
Control                           Hand1
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5 CONCLUSIONS
− We have identified new genes regulated by HMGA1 proteins.
− HMGA1 proteins are implicated in many different pathways since we have
found that the genes regulated by HMGA1 proteins belong to diverse
families and have very diverse roles.
− HMGA1 exert  positive and negative gene regulation since we have found
some of the genes  up-regulated and some down-regulated by HMGA1
proteins.
− We have found that the regulation is tissue-specific since likely depending
on the multiprotein complex in which HMGA1 proteins are inserted.
− We have demonstrated that the regulation is direct in some cases, such as
Id3, p96 and Hand1.
−  For Hand1, we have studied the role in transformation and we show
evidence that Hand1 down-regulation by HMGA1 proteins may account
for the malignant phenotype in human thyroid carcinomas.
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ABSTRACT
High mobility group A (HMGA) proteins are chromatinic proteins that
do not have transcriptional activity per se, however, by interacting with
the transcription machinery, they regulate, negatively or positively, the
expression of several genes. We searched for genes regulated by HMGA1
proteins using microarray analysis in embryonic stem (ES) cells bearing
one or two disrupted hmga1 alleles. We identified 87 transcripts increased
and 163 transcripts decreased of at least 4-fold in hmga1/ ES cells. For
some of them, a HMGA1-dose dependency was observed, because an
intermediate level was observed in the heterozygous ES cells. When the
expression analysis of these genes was extended to embryonic fibroblasts
and adult tissues such as heart, spleen, and liver from hmga1-knockout
mice, contrasting results were obtained. In fact, aside some genes showing
the same HMGA1 regulation observed in ES cells, there were some genes
that did not modify their expression, and others showing a HMGA1-
mediated regulation but in an opposite direction. These results clearly
indicate that HMGA1-mediated gene regulation depends on the cellular
context. Finally for a couple of analyzed HMGA1-regulated genes, elec-
trophoretic mobility shift assay and chromatin immunoprecipitation re-
vealed a direct binding of HMGA1 proteins to their promoters, suggesting
a HMGA1-direct regulation of their expression.
INTRODUCTION
The high mobility group A (HMGA) protein family includes
HMGA1a and HMGA1b, which are encoded by hmga1 through
alternative splicing (1) and the closely related HMGA2 protein (2).
These proteins bind the minor groove of AT-rich DNA sequences.
Their DNA-binding domain is located in the NH2-terminal region of
the protein and contains three short basic repeats, the so-called “AT-
hooks.” The mammalian HMGA proteins have long been known to
play key roles in chromatin architecture and gene control by serving
as generalized chromatin effectors, either enhancing or suppressing
the ability of more usual transcriptional activators and repressors to
act within the confines of chromatinized DNA (3, 4).
HMGA1 proteins seem to play their major physiological role dur-
ing embryonic development (5). In fact, HMGA1 expression is very
high during embryogenesis, whereas it is negligible in normal adult
tissues. HMGA1 proteins has been found abundant in malignant
neoplasias (6), where their expression appears critical for the acqui-
sition of the neoplastic phenotype (7, 8).
To identify the differentiation pathways in which HMGA1 is in-
volved and to assess the role of the HMGA1 proteins in development,
we generated embryonic stem (ES) cells in which one or both hmga1
alleles are disrupted. We reported recently that hmga1/ ES cells
generate less T-cell precursors than do wild-type ES cells after in
vitro-specific differentiation. Indeed, they preferentially differentiate
to B cells, probably consequent to decreased IL-2 expression and
increased IL-6 expression, both of which are regulated directly by the
HMGA1 proteins (9). Moreover, a lack of HMGA1 expression results
in altered hemopoietic differentiation (i.e., there is a reduction in the
monocyte/macrophage population and an increase in megakaryocyte
precursors, erythropoiesis, and globin gene expression). Re-expres-
sion of the hmga1 gene in hmga1/ ES cells restores the wild-type
phenotype (9). These results indicate that drastic changes occur in the
transcriptional activity of the hmga1/ cells, and presumably they
depend on the modification of the expression of HMGA1-regulated
genes.
Using the powerful oligonucleotide microarray hybridization tech-
nique, we analyzed the expression profile of ES cells carrying two,
one, and no hmga1 functional alleles to identify the genes that are
regulated, positively or negatively, by HMGA1. We screened an array
in which 13,059 transcripts were represented, and we identified 87
transcripts that increased and 163 transcripts that decreased with a
4-fold change in hmga1/ ES cells with respect to the wild-type
ES cells. Semiquantitative and quantitative reverse transcription (RT)-
PCR confirmed the differential expression between wild-type and
hmga1-knockout ES cells. We obtained different results when we
measured the expression of these genes in murine embryonic fibro-
blasts (MEF) and various adult tissues from hmga1 knockout mice.
The differential expression of some genes matched that found in ES
cells, whereas the expression of other genes was either unchanged or
opposite to that found in ES cells. Finally, electrophoretic mobility
shift assay and chromatin immunoprecipitation experiments demon-
strated that HMGA1 proteins bind to the promoters of some repre-
sentative HMGA1-regulated genes, indicating a direct role of
HMGA1 in the regulation of their transcription.
MATERIALS AND METHODS
Cell Culture. The generation and the culture of hmga1/ and
hmga1/ ES cells are described elsewhere (9). MEF have been established
from wild-type, hmga1/ and hmga1/ embryos 12.5 days post-coitum
following standard procedures. They were grown in DMEM medium supple-
mented with 10% FCS, glutamine and non-essential aminoacids (Life Tech-
nologies, Inc.) in a 7% CO2 atmosphere. Functioning rat thyroid line
(FRTL)-5, FRTL-5-KiMSV and FRTL-5–HMGA1as-KiMSV cells, and their
culture conditions are reported elsewhere (8).
RNA Extraction from Tissues and Cells. Tissues were snap-frozen in
liquid nitrogen and stored at80°C until use. Total RNAs were extracted from
tissues and cell culture using TRI REAGENT (Molecular Research Center,
Inc.) solution, according to the manufacturer’s instructions. The integrity of the
Received 4/21/04; revised 6/17/04; accepted 6/23/04.
Grant support: from the Associazione Italiana Ricerca sul Cancro (AIRC), Progetto
Strategico Oncologia Consiglio Nazionale delle Ricerche, the Ministero dell’Universita` e
della Ricerca Scientifica e Tecnologica (MIUR), “Piani di Potenziamento della Rete
Scientifica e Tecnologica” CLUSTER C-04, and the Programma Italia-USA sulla Terapia
dei Tumori coordinated by Prof. Cesare Peschle, and Ministero della Salute.”
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Alfredo Fusco, Dipartimento di Biologia e Patologia Cellulare
e Molecolare e/o Instituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facolta`
di Medicina e Chirurgia di Napoli, Universita` degli Studi di Napoli “Federico II,” via
Pansini 5, 80131 Napoles, Italy. Phone: 39-081-746-3749 or 3056; fax: 39-081-746-3037;
E-mail: afusco@napoli.com.
5728
RNA was assessed by denaturing agarose gel electrophoresis (virtual presence
of sharp 28S and 18S bands) and spectrophotometry.
Microarray Analysis. Microarray analysis was performed as described
previously in detail.5 Briefly, cRNA was prepared from 8 g of total RNA,
hybridized to MG-U74 Affymetrix oligonucleotide arrays (containing 13,059
murine transcripts), scanned, and analyzed according to Affymetrix (Santa
Clara, CA) protocols. Scanned image files were visually inspected for artifacts
and normalized by using GENECHIP 3.3 software (Affymetrix). Comparisons
were made for each mutated sample versus wild-type sample, taking the
wild-type sample as baseline by using GENECHIP 3.3. The fold-change
values, indicating the relative change in the expression levels between mutated
samples and the wild-type sample, were used to identify genes differentially
expressed between these conditions.
Semiquantitative and Quantitative RT-PCR. RNAs were treated with
DNaseI (Invitrogen) and reverse-transcribed using random exonucleotides as
primers and MuLV-reverse transcriptase (Perkin-Elmer). To ensure that RNA
samples were not contaminated with DNA, negative controls were obtained by
performing PCR on samples that were not reversed-transcribed but otherwise
identically processed.
The PCRs were performed with the same RNAs used for array analysis, and
the primers sequences are available upon request. For semiquantitative PCR,
reactions were optimized for the number of cycles to ensure product intensity
within the linear phase of amplification. The PCR products were separated on
a 2% agarose gel, stained with ethidium bromide, and scanned using a
Typhoon 9200 scanner. Digitized data were analyzed using Imagequant (Mo-
lecular Dynamics).
Quantitative PCR was performed with SYBR Green PCR Master Mix
(Applied Biosystems) as follows: 95°C 10 minutes and 40 cycles (95°C 15
seconds and 60°C 1 minute).
Protein Extraction, Western Blotting, and Antibodies. Tissues and cell
culture were lysed in buffer 1% NP40, 1 mmol/L EDTA, 50 mmol/L Tris-HCl
(pH 7.5), and 150 mmol/L NaCl, supplemented with complete protease inhib-
itors mixture (Roche Diagnostic Corp.). Total proteins were separated by
SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). Mem-
branes were blocked with 5% nonfat milk and incubated with antibodies
against Id3 and tubulin. All of them were purchased from Santa Cruz Bio-
technology. Bound antibody was detected by the appropriate secondary anti-
body and revealed with an enhanced chemiluminescence system (Amersham-
Pharmacia Biotech).
Electrophoretic Mobility-Shift Assay. DNA-binding assays with the pu-
rified proteins were performed as described previously (10). Five to 20 ng of
recombinant protein were incubated in the presence of radiolabeled oligonu-
cleotide. A 200-fold excess of specific unlabeled competitor oligonucleotide
was added. The double-strand oligonucleotides used were Id3 spanning from
base 632 to 615 of the murine Id3 promoter region, (5-tgattttttttttttt-
tcaaatctg-3; ref. 11) and p96 spanning from base 901 to 872 of the 5
untranslated region of the murine p96 gene (5-aagaaatatttgatattttttcttttatcc-3;
Ref. 12).
The same oligonucleotides were also used in binding assays with total
extract from wild-type and hmga1-knockout murine spleen tissues. Eight
micrograms of extracts were incubated in 20 mmol/L HEPES (pH 7.6), 40
mmol/L KCl, 0.1 mmol/L EDTA, 0.5 mmol/L MgCl2, 0.5 mmol/L DTT, and
0.1 mmol/L phenylmethylsulfonyl fluoride in a volume of 20 l containing 1
g of poly(dC-dG), 2 g of BSA, and 10% glycerol, for 10 minutes at room
temperature. Binding reactions were incubated for 10 minutes after the addi-
tion of 2.5 fmol of a 32P-end-labeled oligonucleotide (specific activity, 8,000–
20,000 cpm/fmol). For the antibody supershift analysis, the reactions were
performed by preincubating extracts with 0.5 g of antibody anti-HMGA1
(Santa Cruz Biotechnology) on ice for a minimum of 30 minutes.
The DNA-protein complexes were resolved on 6% non-denaturing acryl-
amide gels and visualized by exposure to autoradiographic films.
Chromatin Immunoprecipitation. Approximately 3  107 wild-type and
hmga1-knockout MEF were grown on 75-cm2 dishes and cross-linked by the
addition of formaldehyde (to 1% final concentration) to attached cells. Cross-
linking was allowed to proceed at room temperature for 5 minutes and was
terminated with glycine (final concentration, 0.125 mol/L). Cells were col-
lected and lysed in buffer containing 5 mmol/L PIPES (pH 8.0), 85 mmol/L
KCl, 0.5% NP40, and protease inhibitors (1 mmol/L phenylmethylsulfonyl
fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin), on ice for 10 minutes.
Nuclei were pelleted by centrifugation at 5,000 rpm for 5 minutes at 4°C and
resuspended in buffer containing 50 mmol/L Tris-Cl (pH 8.1), 10 mmol/L
EDTA, 1% SDS, the same protease inhibitors, and incubated on ice for 10
minutes. Chromatin was sonicated on ice to an average length of about 400 bp
with a Branson sonicator model 250. Samples were centrifuged at 14,000 rpm
for 10 minutes at 4°C. Chromatin was pre-cleared with protein G Sepharose
(blocked previously with 1 mg/ml BSA) at 4°C for 2 hours. Pre-cleared
chromatin of each sample was incubated with 2 g of antibody anti-HMGA1
at 4°C overnight. An aliquot of wild-type sample was incubated also with
anti-IgG antibody. Next, 60 l of a 50% slurry of blocked protein G Sepharose
was added, and immune complexes were recovered. The supernatants were
saved as “input.” Immunoprecipitates were washed twice with 2 mmol/L
EDTA, 50 mmol/L Tris-Cl (pH 8.0) buffer and 4 times with 100 mmol/L
Tris-Cl (pH 8.0), 500 mmol/L LiCl, 1% NP40, and 1% deoxycholic acid
buffer. The antibody-bound chromatin was eluted from the beads with 200 l
of elution buffer (50 mmol/L NaHCO3, 1% SDS). Samples were incubated at
67°C for 5 hours in the presence of 10 g RNase and NaCl to a final
concentration of 0.3 mol/L to reverse formaldehyde cross-links. Samples were
then precipitated with ethanol at20°C overnight. Pellets were resuspended in
10 mmol/L Tris (pH 8)-1 mM EDTA and treated with proteinase K to a final
concentration of 0.5 mg/ml at 45°C for 1 hour. DNA was extracted with
phenol/chloroform/isoamyl alcohol, ethanol-precipitated, and resuspended in
water. Input DNA and immunoprecipitated DNAs were analyzed by PCR for
the presence of Id3 and p96 promoter sequences. PCR reactions were per-
formed with AmpliTaq gold DNA polymerase (Perkin-Elmer). The primers
used to amplify the sequence of the Id3 promoter were 5-agggtttatgcagcaag-
cac-3 (forward) and 5-atttgctgctcgtctgacct-3 (reverse). The primers used to
amplify the sequence of the p96 promoter were 5-aactccagctgtgtcaagtt-3
(forward) and 5-gaaagaaagagaggggaaag-3 (reverse). PCR products were re-
solved on a 2% agarose gel, stained with ethidium bromide, and scanned using
a Typhoon 9200 scanner.
RESULTS
Gene Expression Profile Analysis. RNAs extracted from wild-
type, hmga1/ and hmga1/ ES cells were hybridized to MG-
U74 Affymetrix oligonucleotide arrays containing 13,059 transcripts.
The expression profile of the heterozygous and homozygous ES cells
was compared with that of the wild-type ES cells that were used as a
common reference. The number of transcripts increased or decreased
in the heterozygous and the homozygous mutant versus wild-type
sample is shown in the Fig. 1. Of the 13,059 transcripts represented on
the array, 1,300 had a 2- to 3-, 313 had a 3- to 4-, 227 had a 4- to 10-,
5 http://www.cancergenetics.med.ohio-state.edu/microarray.
Fig. 1. Gene expression profile in ES cells carrying one or two hmga1 disrupted alleles.
The expression profile of the heterozygous and the homozygous hmga1-knockout ES cells
was compared with that of the wild-type ES cells that were used as a common reference.
Transcripts are grouped according to fold change.
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Table 1 The genes differentially expressed with a 4-fold change in heterozygous (/) and homozygous (/) hmga1-knockout ES cells were grouped in families
Description
GenBank
accession no. FC / FC /
A. Signal transduction
Mus musculus parathyroid hormone/parathyroid hormone related-peptide receptor (PTHR) gene, exons 10–15, complete cds. L34611 1.1 18.4
M. musculus mRNA for ryudocan core protein, complete cds. D89571 3.9 10.6
M. musculus mitogen-responsive Mr 96,000 phosphoprotein p96 mRNA, alternatively spliced p67 mRNA, and alternatively spliced
p93 mRNA, complete cds.
U18869 1.7 9.3
M. musculus mRNA for MAP kinase-activated protein kinase 2 BC063064 10 4.7
Mouse Wnt-6 mRNA, complete cds. M89800 1.1 4.1
M. musculus JIP-1 (JIP-1) mRNA, complete cds. AF003115 1.7 4
Murine macrophage gene, encoding bmk (B cell/myeloid kinase). J03023 1.4 4.1
M. musculus TGF--inducible protein (TSC-36) mRNA, complete cds. M91380 1.3 4.2
M. musculus mRNA for retinoic acid receptor-. X57528 1.1 4.3
Mouse growth factor-inducible protein (pip92) mRNA, complete cds. M59821 2.5 4.4
Mouse oxytocin-neurophysin I gene, complete cds. M88355 1.7 4.5
M. musculus-patched mRNA, complete cds U46155 1.2 4.6
Mouse G protein  subunit (GNA-15) mRNA, complete cds. M80632 9.4 4.7
Mouse mRNA for NBL4, complete cds. D28818 2.1 5.1
M. musculus receptor protein tyrosine phosphatase- (ptp-) mRNA, complete cds. U55057 1.3 5.4
M. musculus protein-serine/threonine kinase (pim-2) mRNA, complete cds. L41495 1.7 5.6
Mouse (clone M1) GTPase (Ran) mRNA, complete cds L32751 2.6 5.7
M. musculus ShcC mRNA, complete cds. U46854 1.3 6.3
M. musculus syk mRNA for protein-tyrosine kinase. Z49877 1.3 6.3
M. musculus c-Src kinase (Csk) mRNA, complete cds. U05247 1.6 8.6
B. Transcription factors
M. musculus Thing1 mRNA, complete cds. U21226 3.8 14
House mouse; Musculus domesticus adult testis mRNA for truncated form of Sox17, complete cds. D49473 1.3 13.7
M. musculus melanocyte-specific gene 1 (msg1) mRNA, complete cds. U65091 1.4 9.7
M. musculus mRNA for fos-related antigen-2 X83971 3.1 4
M. musculus Sox4 (Sox4) mRNA, partial cds. ET62444 1.4 4.1
Mouse c-fos oncogene. V00727 12 4.2
Mouse c-myc gene exon 3. L00039 4.3 4.3
M. musculus AP-2.2 gene. X94694 1.6 4.4
Mouse mRNA for Zfp-57, complete cds. D21850 2.5 4.6
M. musculus Kruppel-like factor LKLF mRNA, complete cds. U25096 1.4 4.8
M. musculus transcription factor TFEB mRNA, partial cds. U36393 2.2 4.9
M. musculus transcription factor NF-YC subunit mRNA, complete cds U62297 2.6 5.2
M. musculus DNA binding protein NFI-X (NfiX) mRNA, partial cds U57636 1.9 6.2
M. musculus mRNA for TIF1  protein X99644 5.8 6.2
M. musculus transcription factor junB (junB) gene, 5 region and complete cds. U20735 3.5 6.4
M. musculus Oct-6 mRNA for octamer binding protein. X57482 8.1 6.5
Mouse helix-loop-helix protein (Id related) mRNA, complete cds. M60523 5.3 7.4
Mouse growth factor-induced protein (zif/268) mRNA, complete cds. M22326 8.2 24.9
C. Cell proliferation
M. musculus chop-10 mRNA. X67083 15.1 16.9
Mouse D-type cyclin (CYL2) mRNA, complete cds. M83749 2.5 9
M. musculus gly96 mRNA. X67644 4.4 8
M. musculus mRNA for zyxin. Y07711 1.3 5.3
D. Extracellular-matrix and cellular-structure
M. musculus laminin A chain mRNA, complete cds. J04064 1.2 14
M. musculus -2 type IV collagen mRNA, complete cds. J04695 1.4 9.8
M. musculus -1 type IV collagen (Col4a-1) mRNA, complete cds. J04694 1.4 9.1
Mouse -B2-crystallin gene, complete cds M73741 1.4 7.7
Mouse laminin B1 mRNA, complete cds. M15525 1.3 6.3
Mouse mRNA for cysteine-rich glycoprotein SPARC NM_009242 1.2 5.5
Mouse gelsolin gene, complete cds. J04953 1.5 4.5
M. musculus mRNA for hair keratin, mHb6. X99143 3.5 4.1
Mouse -B crystallin mRNA. M63170 1 4
Mouse COL1A2 mRNA for pro--2(I) collagen. X58251 3.8 4.1
M. musculus B gene. X99963 7.4 4.2
M. musculus neurofibromatosis 2 (Nf-2) gene mRNA, complete cds. L27090 1.3 4.5
M. musculus SM22  mRNA, complete cds. L41154 1.5 4.5
Mouse COL1A2 mRNA for pro--2(I) collagen NM_007743 3.9 4.7
M. musculus  1 type I collagen gene, partial cds and 3 flanking region U50767 1.9 5.6
M. musculus mRNA for myosin I X97650 4.6 6.3
Mouse tau microtubule binding protein mRNA, complete cds. M18776 1.3 6.6
M. musculus FVB/N collagen pro--1 type I chain mRNA, complete cds. U08020 2.1 7.5
Mouse mRNA for vascular smooth muscle -actin. X13297 2.1 8.6
E. Metabolism, transport and secretion
Mouse mRNA for mastocytoma proteoglycan core protein, serglycin. X16133 2.6 40.9
M. musculus cathepsin H prepropeptide (ctsH) mRNA, complete cds. U06119 1.5 17.3
M. musculus calcium binding protein D-9k mRNA, complete cds. AF028071 2.3 9.8
Mouse serine protease inhibitor homologue (J6) mRNA, complete cds J05609 1.7 8.7
M. musculus heparan sulfate D-glucosaminyl 3-O-sulfotransferase-1 precursor (3OST1) mRNA, alternatively spliced, complete cds. AF019385 1.4 6.5
Mouse mRNA for preproinsulin-like growth factor IA. X04480 1.5 6.2
M. musculus preprodipeptidyl peptidase I mRNA, complete cds. U89269 1.2 5.9
M. musculus mRNA for cytoplasmic dynein heavy chain (partial, ID mdhc10). ET63396 1.6 5.5
M. musculus steroid cytochrome p450 7- hydroxylase mRNA, complete cds. L06463 1.1 4
M. musculus very-long-chain acyl-CoA synthetase (VLCS) mRNA, complete cds. AF033031 2 4
M. musculus (clone E31.1 in pGEM7Zf()) N-acetylglucosaminyltransferase I mRNA, complete cds. L07037 2.5 4.1
Mouse mRNA for inward rectifier K channel, complete cds. D50581 1 4.1
M. musculus preprocortistatin (Cort) mRNA, complete cds. AF013253 2.7 4.3
M. musculus extracellular superoxide dismutase (SOD3) mRNA, complete cds. U38261 1.2 4.6
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Fig. 2. Validation of microarray data by semiquantitative and quan-
titative RT-PCR. We confirmed some of the microarray data by semi-
quantitative (A) or quantitative (B) RT-PCR. Amplification of the -
actin gene has been evaluated as a control of the RNA amount used. Cpe,
carboxypeptidase E.
Table 1 Continued
Description
GenBank
accession no. FC / FC /
Mouse mRNA for a preprothyrotropin-releasing hormone. X59387 1.1 4.7
M. musculus steroid sulfatase (Sts) mRNA, complete cds. U37545 2.3 4.7
M. musculus mRNA for dihydropyrimidinase related protein 4, complete cds. AB006715 5.7 4.9
M. musculus putative chloride channel protein CLC6 (Clc6), exon 23 and complete cds. AF030106 1 4.9
Mouse placental alkaline phospatase mRNA, complete cds. J02980 1.1 4.9
M. musculus Balb/c cytochrome c oxidase subunit VIaH mRNA, complete cds. U08439 3.1 5
Mouse metallothionein-III gene, complete cds. M93310 1.4 5.3
M. musculus carboxypeptidase E (Cpe) mRNA, complete cds. U23184 3.5 5.8
M. musculus hormone-sensitive lipase mRNA, complete cds. U08188 1.7 8
M. musculus ADP-ribosylation factor-like protein 4 mRNA, complete cds. U76546 2.4 8.7
F. Growth factors and related proteins
M. musculus lefty gene. AJ000083 1.1 4.3
M. musculus mRNA for insulin-like growth factor binding protein-3 X81581 3.2 6.4
M. musculus mRNA for insulin-like growth factor binding protein-4. X81582 1.4 7.3
M. musculus acid labile subunit (ALS) gene, complete cds. U66900 2.4 7.4
Mouse Cyr61 mRNA, complete cds. M32490 4.2 8.4
M. musculus follistatin-like protein (mac25) mRNA, complete cds. L75822 2.6 11
G. Immune functions
Mouse gene for Mr 47,000 heat shock protein(HSP47), exon 6. D12907 1.1 5.7
M. musculus MHC class I B(2)-microglobulin gene (W4 allele), partial cds M84366 1.2 5
Mouse lymphocyte differentiation antigen (Ly-6.2) mRNA, complete cds. M18184 1.7 4.9
M. musculus anti-digoxin immunoglobulin heavy chain variable region precursor mRNA, partial cds. ET62206 2 4.7
Mouse CD19 gene, exons 6–15. M62553 3.3 4.1
M. musculus (clone B6) myeloid secondary granule protein mRNA. L37297 2 4.3
M. musculus putative TNF-resistance related protein mRNA, complete cds. U90926 1.5 6.5
Mouse mRNA for poliovirus receptor homolog protein soluble form, complete cds. D26107 3.7 12.2
H. Other functions
Mouse surfeit locus surfeit 3 protein gene M14689 3.3 4.5
Mouse ERA-1–993 mRNA, complete cds, and alternate ERA-1–339 mRNA, complete cds. M22115 3.3 4.1
M. musculus imprinted in placenta and liver (Ipl) gene, complete cds. AF002708 1.7 4.1
M. musculus H19 mRNA. X58196 2.6 5.9
Abbreviations: cds., coding sequence; FC, fold change.
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and 23 had a 10-fold change. We examined the 250 transcripts
(1.9%) that had a 4-fold-change in the homozygous mutant versus
the wild-type sample. Among these 250 transcripts, 87 were increased
and 163 were decreased, including 103 known genes (37 increased
and 66 decreased), 118 expression sequence tags (ESTs) (40 in-
creased and 78 decreased), and 29 unknown genes (10 increased and
19 decreased). As a control of microarray analysis, we verified that
the HMGA1 was not expressed in hmga1/ ES cells. The genes
with 4-fold change in hmga1/ ES cells were grouped according
to their function: (a) signal-transduction pathways, (b) transcription
factors, (c) cell proliferation, (d) extracellular-matrix and cellular-
structure proteins, (e) metabolic pathways, transport and secretion, (f)
growth factors and related proteins, (g) genes with immune functions,
and (h) other genes. The relative fold changes in these genes, grouped
as described above, are shown in Table 1. It is noteworthy that among
the HMGA1-regulated genes, we found Id3 (13), lefty (14), and
Wnt-6 (15) that are important in embryonic development and some
oncogenes such as c-myc, junB, pim-2, and c-fos.
Validation of Microarray Analysis. To validate the results ob-
tained by microarray analysis we evaluated the expression of 50
transcripts by semiquantitative RT-PCR in the wild-type,
hmga1/ and hmga1/ ES cells. For all of them, RT-PCR
analysis confirmed the differential expression associated with the
expression of the HMGA1 proteins. Some representative RT-PCR
analysis are shown in Fig. 2A. The expression of some genes (i.e.,
TFEB, LKLF, and Id3) was hmga1 dose-dependent. In fact, the
changes in hmga1/ ES cells were intermediate between those
found in wild-type and hmga1/ ES cells. Conversely, the
expression of other genes (i.e., cubilin, p96, D-9K, legumain, and
collagen) was not modified in hmga1/ ES cells in comparison
to the wild-type ES cells. We also analyzed 12 genes with quan-
titative RT-PCR. The results coincide with those of the microarray
analysis (Fig. 2B). The primers used for semiquantitative and
quantitative PCR are available upon request.
Some, but Not All, of the Genes Differentially Expressed in
Wild-Type and hmga1-Knockout ES Cells Depend on HMGA1
Expression in Other Cells and Tissues. We next verified whether
the genes differentially expressed in hmga1-knockout ES cells
showed a differential expression also in embryonic fibroblasts isolated
from hmga1-knockout mice. A semiquantitative RT-PCR analysis
showed that the differential expression of some genes (i.e., D-9k, gly
96, and LKLF) in hmga1/ fibroblasts matched that found in
hmga1-knockout ES cells, whereas the expression of other genes did
not (Fig. 3A). We next evaluated the expression of the HMGA1-
regulated genes in adult heart, liver, and spleen tissue from
hmga1/ and hmga1/ mice.
Some genes, such as Id3 and p96, showed the same expression
trend as in ES cells, being down-regulated and up-regulated by
HMGA1, respectively, also in heart and spleen (Fig. 3A). Some other
genes only changed in one type of tissue. For example, gly96 and
LKLF expression was different only in spleen, whereas TFEB and
Laminin 1 were different only in heart. Interestingly, the regulation
of some genes, such as TFEB and Laminin 1, in adult tissues was
opposite to that found in ES cells. In fact, they were decreased in ES
cells but increased in heart (Fig. 3A). These results suggest that
HMGA1 function depends on the cellular context.
To verify that changes in RNA levels were associated with changes
at protein levels, we analyzed by Western blot the expression of Id3
in MEF and tissues from wild-type and hmga1-knockout mice. As
shown in the Fig. 3B for the Id3 protein, protein levels paralleled RNA
levels and were characteristic in each tissue.
Fig. 3. Gene expression in hmga1-knockout cells and tissues. A,
gene expression analysis by semiquantitative RT-PCR in hmga1-
knockout MEFs and tissues. -Actin has been used as a housekeep-
ing gene to normalize the RNA amount used. B, protein expression
analysis by Western blot in hmga1-knockout MEFs and tissues. As
a control for equal protein loading, the blotted proteins were incu-
bated with -tubulin-specific antibodies. The sources of proteins are
indicated. Cpe, carboxypeptidase E.
5732
GENES REGULATED BY HMGA1
Analysis of the HMGA1-Dependent Genes in a Transformed
Cell System. We demonstrated previously that HMGA1 overexpres-
sion is a necessary event in cell transformation. In fact, when HMGA1
expression was blocked by transfecting rat thyroid cells (FRTL-5)
with an antisense hmga1 cDNA construct and infected with the
Kirsten murine sarcoma virus (KiMSV) carrying the v-ras-Ki onco-
gene, they (FRTL-5-HMGA1as-KiMSV) did not acquire the typical
markers of neoplastic transformation (ability to grow in soft agar and
induce tumors after injection into athymic mice), although the differ-
entiation markers (i.e., thyrotropin-dependency, ability to trap iodide,
thyroglobulin synthesis, and secretion) were lost. Conversely, the
neoplastic markers were shown by the untransfected rat thyroid cells
infected with the same murine retrovirus (FRTL-5-KiMSV; ref. 8).
Therefore, we analyzed, by semiquantitative and quantitative RT-
PCR, the expression of some hmga1-dependent genes in FRTL-5,
FRTL-5-KiMSV, and FRTL-5-HMGA1as-KiMSV cells. The experi-
ments revealed two sets of genes. Some genes showed the same
regulation observed in the ES cells, i.e., carboxypeptidase E (Cpe) that
decreased in hmga1-knockout ES cells and increased in the neoplastic
cells or cathepsin H that increased in hmga1-knockout ES cells and
decreased in the neoplastic cells compared with the wild-type con-
trols. Other genes were regulated in an opposite direction compared
with ES cells (i.e., p96 and mac25), which demonstrated an increased
and a decreased level, respectively, in both hmga1-knockout ES and
the FRTL5 KiMSV cells compared with the respective controls,
although the HMGA1 proteins were expressed only in the latter cells.
Some representative results are shown in Fig. 4, A and B. In Fig. 4C
we show the expression of the proteins v-ras-Ki and HMGA1 in the
normal and neoplastic thyroid cells.
HMGA1 Proteins Bind to Id3 and p96 Promoters. We next
evaluated whether the differential gene expression was a direct effect
of the presence of HMGA1. We examined the Id3 and p96 genes
because they were modified at RNA level in different cells and tissues
and because their promoter regions contain AT-rich sequences that are
a preferential-binding site for the HMGA proteins.
To investigate whether the HMGA1 proteins were able to bind the
AT-rich promoter regions of both Id3 and p96, we performed an
electrophoretic mobility shift assay using oligonucleotides spanning
nucleotides 632 to 615 of the murine Id3 promoter region and
901 to 872 of the 5 untranslated region of the murine p96 gene.
As shown in Fig. 5A, a recombinant HMGA1 protein was able to bind
directly to these regions. Binding specificity was demonstrated by
competition experiments showing loss of binding with the addition of
200-fold molar excess of a specific unlabeled oligonucleotide. Sub-
sequently, we performed binding assays with total extract from wild-
type and hmga1-knockout murine spleens. Two specific complexes
with mobility corresponding to the HMGA1 proteins (isoforms A1a
and A1b) were present in extracts from wild-type and heterozygous
(data not shown) spleens, whereas they were absent in extracts from
homozygous hmga1-knockout mice (Fig. 5B). These complexes were
Fig. 4. Gene expression in a transformed cell system-overexpress-
ing HMGA1. The expression of some genes has been studied by
semiquantitative (A) or quantitative (B) RT-PCR in a transformed cell
system overexpressing HMGA1; -actin has been used as a house-
keeping gene to normalize the RNA amount used; (C) Western blot
analysis of v-ras-Ki and HMGA1 proteins. Sources of RNA or pro-
teins are FRTL-5, rat thyroid epithelial cell line; FRTL-5-KiMSV,
FRTL-5 infected with the Kirsten murine sarcoma virus; FRTL-5-
HMGA1as-KiMSV, FRTL-5 transfected with a construct carrying
HMGA1 mRNA in an antisense orientation, and then infected with the
Kirsten murine sarcoma virus.
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specifically displaced by the incubation with an antibody directed
against the HMGA1 proteins, demonstrating that these complexes do
consist of the HMGA1 proteins (Fig. 5B). A control gel shift for Sp1
was performed to normalize the spleen extracts used (Panel C).
To verify that HMGA1 proteins bind to Id3 and p96 promoters in
vivo, we performed experiments of chromatin immunoprecipitation in
MEF from wild-type and hmga1-knockout mice. Chromatin prepared
as described under Materials and Methods was immunoprecipitated
with anti-HMGA1 or normal rabbit IgG antibodies. The results shown
in Fig. 5D demonstrate that HMGA1 proteins bind to these promoters.
In fact, the Id3 and p96 promoter regions were amplified from the
DNA recovered with anti-HMGA1 antibody in wild-type and
hmga1/ but not in hmga1/ MEFs. Moreover, no amplification
was observed in samples immunoprecipitated with normal rabbit IgG.
DISCUSSION
We have analyzed the expression profile of ES cells carrying two,
one, and no hmga1 functional allele by screening an “Affymetrix
microarray” to identify genes that are regulated, positively or nega-
tively, by the HMGA1 proteins. We found 87 transcripts increased
and 163 decreased with a 4-fold change in hmga1/ ES cells. The
validity of these assays was confirmed by the absence of HMGA1
expression in the ES knockout cells. Semiquantitative and quantitative
RT-PCR confirmed that all of these genes were differentially ex-
pressed in wild-type and hmga1-knockout ES cells. Several genes
displayed hmga1 dose-dependency, the phenotype of heterozygous
cells was intermediate between those of wild-type and homozygous
knockout cells. Thus for some genes, the level of hmga1 expression
may be critical for appropriate gene expression. In this case both
alleles seem to be necessary to regulate the expression of these genes.
For some other genes, the dependency on the hmga1 expression levels
was even more pronounced because the gene expression level in
heterozygous ES cells was very close to that observed in homozygous
cells. This type of regulation by hmga1 expression levels may explain
the appearance of pathologies, such as cardiac hypertrophy and B cell
lymphomas, in mice heterozygous for hmga1 gene disruption.6 Sev-
eral other genes showed the same expression level in wild-type and
heterozygous ES cells. In this case, one hmga1 allele is sufficient to
regulate gene expression.
The genes regulated by HMGA1 in ES cells were also analyzed in
MEF and in liver, spleen, and heart from wild-type, hmga1/ and
hmga1/ mice. Different results were obtained in comparison to
those observed in ES cells. In fact, the expression of some genes was
either not modified by hmga1 gene expression, or their regulation
occurred in an opposite direction. It is noteworthy that the HMGA1
regulation of several genes was cell- and tissue-specific. It is known
that by interacting with partner proteins, the HMGA1 proteins are able
to enhance or suppress the effect of more “traditional” transcriptional
activators and repressors. The fact that partner proteins are critical for
HMGA1 activity may account for the cell- and tissue-specific regu-
lation exerted by the HMGA1 proteins.
The same occurred when the HMGA1-regulated genes in ES were
investigated in a cell system constituted by normal rat thyroid cells
(FRTL-5) that do not express the HMGA1 proteins, the same cells
6 M. Fedele, V. Fidanza, S. Battista, A. Fusco, manuscript in preparation.
Fig. 5. HMGA1 proteins bind murine Id3 and p96 promoters in vitro
and in vivo. A, electrophoretic mobility shift assay performed with radio-
labeled oligonucleotides spanning from 209 to 169 bp of the murine
Id3 promoter, spanning from 901 to 872 of the 5 untranslated region
of the murine p96 gene, and incubated with increasing amounts of recom-
binant HMGA1 as indicated. To assess the specificity of the binding, a
200 excess of unlabeled oligonucleotides were incubated as specific
competitors. B, electrophoretic mobility shift assay performed with the
same oligonucleotides as in panel A, incubated with total extracts from
wild-type and hmga1-knockout murine spleens. In total extracts from
wild-type (hmga1/) spleens there were two specific complexes, absent
in total extracts from homozygous (hmga1/) spleen. Anti-HMGA1
antibody was used as a specific competitor. C, a control gel shift for Sp1
was performed to normalize the spleen extracts used. D, chromatin im-
mune precipitation assay was performed on wild-type and hmga1-knock-
out MEFs. The recovered DNA was used as a template for PCR reactions
with primers that amplify the murine Id3 and p96 promoters.
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malignantly transformed by the KiMSV (FRTL-5-KiMSV) that ex-
press high-HMGA1 levels and FRTL-5-KiMSV cells in which the
synthesis of the HMGA1 protein was blocked by an antisense con-
struct (FRTL-5-HMGA1as-KiMSV). These experiments revealed two
sets of genes, those showing the same kind of regulation observed in
ES and those genes showing regulation that occurred in an opposite
direction.
The differential gene expression depending on the HMGA1 pres-
ence could depend on an indirect effect of the HMGA1 proteins in the
sense that HMGA1 might induce some proteins that may interfere
with the expression of some genes. To exclude this possibility and
demonstrate a direct effect of HMGA1 on the regulation of some
genes expressed differentially in hmga1-knockout cells, we performed
electrophoretic mobility shift assay and chromatin immunoprecipita-
tion experiments. We demonstrated the binding of the HMGA1 pro-
teins to the promoters of Id3 and p96. We note of particular interest
the finding that p96 and Id3 are regulated by the HMGA1 proteins
because they are believed to have a critical role in the process of
carcinogenesis. In fact, although no putative alterations on Id genes
have been identified in primary human tumors to date to certify Ids as
true cellular proto-oncogenes, Id proteins that are basic helix-loop-
helix transcription factors have been implicated in regulating a variety
of cellular processes (i.e., cellular growth, senescence, differentiation,
apoptosis, and angiogenesis) that regulate tumorigenesis (16). In
particular, Id3 has been frequently found increased in human neopla-
sias (16). Equally, p96, a mitogen-responsive phosphoprotein cloned
from a mouse macrophage cell expression library, is consistently
down-regulated in mouse mammary carcinogenesis and in human
ovarian carcinomas as compared with normal surface epithelium (17,
18). It is likely that Id3 up-regulation and p96 down-regulation in
human neoplasias depend also on the HMGA1 overexpression, a
feature of most of the human-malignant neoplasias (19).
When we analyzed the expression of some genes in MEF and adult
tissues taken from HMGA2 knockout mice, we found that several
genes do not appear to be regulated by HMGA2 (data not shown).
This result could depend on the different action of these two members
of the same HMGA protein family and confirms that although
HMGA1 and HMGA2 have a similar structure and expression profile
(high during embryogenesis and neoplastic tissue), they exert different
functions. This is consistent with a body of evidence indicating that
the two proteins exert different function: (a) the BRCA1 promoter is
regulated negatively by HMGA1 but not by HMGA2 (20); (b)
HMGA2 is critical for adipocytic cell growth (21, 22), whereas
HMGA1 has negative effect on the growth of the preadipocytic cells
3T3 L1 (23); and (c) the phenotype of the hmga1- and hmga2-
knockout mice is divergent: i.e., a reduction in size and fat tissue of
hmga2-null mice and in cardiac hypertrophy and B-cell lymphomas of
hmga1-null mice.7
In conclusion, this study indicates that HMGA1 proteins are in-
volved in the regulation of several genes. For some genes, such as Id3
and p96, we demonstrate that the regulation is direct. The positive or
negative regulation appears to be tissue-specific because it likely
depends on the multiprotein complex in which HMGA1 proteins are
inserted.
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 Abstract. Glioblastoma is one of the most aggressive tumors
in mankind with 50% of patients dying within the 1st year of
diagnosis, and being refractory to conventional therapies. The
aim of our work has been to analyse the expression of the
HMGA1 proteins in human astrocytomas and glioblastomas in
order to verify whether the detection of these proteins might be
of some help in the diagnosis of these neoplasias. Here we
report the analysis of 27 cases, including 12 astrocytomas and
15 glioblastomas, for HMGA1 expression. All the neoplastic
samples showed positive staining even though the number of
positive cells and the staining intensity was higher in glio-
blastomas compared to astrocytomas. Conversely, HMGA1
proteins were not detected in normal brain. Accordingly,
expression of the hmga1 gene, analysed by RT-PCR, was
higher in glioblastomas than in astrocytomas.
Introduction
The incidence of all adult primary brain tumors is 11.8 per
100,000 person-years, with malignant primary glial tumors
representing 6.5 per 100,000 person-years (20). Most adult
supratentorial gliomas are forms of astrocytomas which
account for >60% of all primary brain tumors.
The current WHO histologic classification of tumors of
the Central Nervous System classifies among astrocytic
tumors the diffusely infiltrating astrocytoma which can be
divided into 3 clinicopathologic entities: diffuse astrocytomas
(WHO grade II), anaplastic astrocytoma (WHO grade III)
and glioblastoma multiforme (WHO grade IV). Such group
of tumors is linked to a survival ranging between >5 years
(diffuse astrocytoma) to <1 year (glioblastoma) with a possible
progression from ‘low grade’ to ‘high grade’ tumors (17). 
The majority of glioblastomas arise without clinical or
histological evidence of a less malignant precursor lesion and
these lesions have been designated primary glioblastoma.
They manifest in older patients (mean age, 55 years) after a
short clinical history of usually <3 months. These primary
glioblastomas are characterized by EGFR amplification
(~40% of cases) and/or overexpression (60%), PTEN mutations
(30%), p16INK4a deletion (30-40%), MDM2 amplification
(<10%) and/or overexpression (50%), and in 50-80% of cases,
loss of heterozygosity (LOH) on the entire chromosome 10.
In contrast, secondary glioblastomas develop more slowly by
malignant progression from diffuse or anaplastic astrocytoma
and manifest in younger patients (mean age, 40 years).
Secondary glioblastomas contain TP53 mutations in ~60% of
cases (18). 
The HMGA proteins are involved in the regulation of
chromatin structure and interact with the basal transcription
machinery regulating the expression of several genes (19,6,12).
HMGA proteins are expressed at low levels in normal adult
tissues, whereas an abundant expression occurs during embryo-
genesis and in several human carcinomas (21). It has been
also demonstrated that the expression level of the HMGA1
proteins is significantly correlated with parameters known to
indicate a poor prognosis in patients with colorectal cancer
(2) and also that HMGA1 could serve as a potential diagnostic
molecular marker for distinguishing pancreatic malignancies
from normal tissues or benign lesions (1).
Therefore, the aim of our work has been to analyse the
expression of the HMGA1 proteins in human astrocytomas and
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RT-PCR
glioblastomas in order to verify whether the detection of these
proteins might be of some help in the diagnosis of these
neoplasias, and whether a possible therapeutic approach
based on the suppression of the HMGA1 protein synthesis
might be taken in consideration, since it has been already
demonstrated that the block of the synthesis of these proteins
causes apoptotic death of carcinoma cells of different tissue
origin (22).
Here we report the analysis of 27 cases including, 12
astrocytomas and 15 glioblastomas for HMGA1 expression.
All the neoplastic samples showed positive staining even
though the number of positive cells and the staining intensity
was higher in glioblastomas compared to astrocytomas.
Conversely, HMGA1 proteins were not detected in normal
brain. 
Materials and methods
Human tissues. Archival formalin-fixed and paraffin-embedded
tissues from the Department of Pathology of the School of
Medicine of the University of Catanzaro and from the Division
of Pathology of Hospital ‘A. Pugliese’ of Catanzaro were used
to study tumors from 27 patients (comprising 12 astrocytomas
- age 24.2±5.2 years, and 15 glioblastomas - age 58.3±4.2)
who underwent their surgical intervention at the Neuro-
surgical Clinics of the University of Catanzaro. Blocks from
3 normal brains obtained at post-mortem examination were
also used as control. 
Seriated deparaffinated sections (4 µm-thick) were used
for staining procedures, hematoxylin and eosin and immuno-
cytochemistry. All procedures were carried out at room
temperature. The slides were treated in a microwave oven
(750 W) twice for 5 min in 10 nM citrate buffer (pH 6.0) for
demascation of the antigen followed by incubation in 0.3%
H2O2 in methanol. Then, 10% goat serum was applied for
30 min followed by a polyclonal anti-HMGA1 product anti-
body (dilution 1:50) for 60 min (8). Biotinylated secondary
antibody (1:60, goat anti-rabbit, Dako, Hamburg, Germany)
and peroxidase-labeled streptavidin (1:100, Dako) were
added in sequence. Diaminobenzidine (Dako) was used as
chromogen. In order to assess cell proliferation, immuno-
histochemical staining with the monoclonal mouse anti-
human anti-human Ki-67 antigen antibody (Clone: MIB-1,
Dako, at a dilution of 1:100) was performed. The slides used
for immunohistochemical procedures were counterstained
with alum-hematoxylin. Cells were counted in tumors (5-fields)
in non-overlapping microscopic fields of a light-microscope
(Zeiss-axioscope) with a 40x objective, and the percentage of
labeled cells was established.
RNA isolation and RT-PCR analysis of the expression of
HMGA1 on astrocytoma and glioblastoma versus normal
brain. RNA extraction from paraffin-embedded samples was
performed following a published procedure (16). Briefly,
single 6-8 µm tissue sections, cut from paraffin blocks, were
stirred for 20 min in 1.5 ml tubes with 1 ml of xylene. After
centrifugation, the pellet was washed with 0.5 ml of ethanol
and air-dried. The dried pellet was resuspended in 200 µl of
6 mg ml-1 proteinase K (Sigma Chemical, St. Louis, MO),
1 M guanidinium thiocyanate, 25 mM 2-mercaptoethanol,
0.5% Sarkosyl, 20 mM Tris-HCl, pH 7.5 and incubated at
37˚C overnight. After centrifugation, the supernatant was
transferred to a new tube where 1 sample equivalent volume
of 70% phenol acid/30% chloroform was added, and the
aqueous supernatant was transferred to a new 1.5 ml tube.
One sample equivalent volume of 25% phenol pH 7/24%
chloroform/1% isoamilic acid was added and the supernatant
was transferred to a new tube containing 1/10 of sample
volume of sodium acetate 3 M pH 5.2, 2 sample volumes of
ethanol 100% and 1 µl of glycogen and was precipitated at
-20˚C overnight. After centrifugation for 15 min at 12,000 x g
in an Eppendorf microcentrifuge, the pellet was washed with
70% ethanol, air-dried and resuspended in H2O. RNA was
reverse transcribed according to manufacturer's instructions
(Perkin-Elmer). The PCR amplification was performed as
follows: denaturation at 95˚C for 5 min, 30 cycles (95˚C,
55˚C and 72˚C for 1 min each temperature) and a final
extension step at 72˚C for 10 min. The sequences of the
forward primers used were for hmga1: 5'-AGAGACCTCGGG
GCCGACCA-3', for ß-actin: 5'-TCGTGCGTGACATTAAGG
AG-3' and the sequences of the reversed primers were for
hmga1: 5'-GATGCCCTCCTCTTCCTCCTT-3', for ß-actin:
5'-GTCAGGCAGCTCGTAGCTCT-3'. To ensure that RNA
samples were not contaminated with DNA, negative
controls were obtained by performing the PCR on samples
that were not reverse-transcribed but otherwise identically
processed.
The PCR products were electrophoresed on a 2% agarose
gel and stained with ethidium bromide. Gels were scanned
using a Typhoon 9200 scanner and digitized data analyzed
using Imagequant (Molecular Dynamics). Hmga1 levels were
normalized to ß-actin gene levels. The resulting values were
normalized versus normal tissue, which received the value of 1.
Fold induction indicates the expression ratio between
glioblastoma and astrocytoma, respectively, versus normal
brain tissue.
Results
Immunohistochemical analysis of HMGA1 expression in
gliomas. Immunohistochemical assay was performed to
evaluate the expression of the HMGA1 proteins in astro-
cytomas and glioblastomas compared with its expression in
normal human brain tissues. The results are summarized in
Table I. In astrocytomas labeling was observed in the nuclei
of tumoral cells. Labeled cells ranged between 49.4-63.2%
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Table I. HMGA1 protein expression in human astrocytomas
and glioblastomas analysed by immunohistochemistry. 
–––––––––––––––––––––––––––––––––––––––––––––––––
Histological No. of positive Mean percentage
type of brain cases/no. of of the
specimens cases analysed stained cells
–––––––––––––––––––––––––––––––––––––––––––––––––
Normal brain 0/4 0
Astrocytomas 12/12 57.3±7
Glioblastomas 15/15 82.3±8
–––––––––––––––––––––––––––––––––––––––––––––––––
(mean 57.3%) in all grade II tumors. Labeling index by
MIB-1 antibody against the Ki-67 antigen, an index of cell
proliferation, was <1%. In glioblastomas, the number of cells
stained by the HMGA1 antibody ranged from 73.2-98.0%
(mean 82.3%) in all tumors. The growth fraction, as
determined by the antibody MIB-1, ranged between 12.3-
32.7% with a mean value of 20.2%. Conversely no HMGA1-
immunostaining at all was observed in normal brain. 
Some representative results of these analyses are shown
in Fig. 1. In glioblastomas, nuclei of neoplastic cells showed
a diffuse HMGA1 expression (Fig. 1D and E). The intensity
of the staining was higher compared to that detected in astro-
cytomas (Fig. 1C). In these tumors, also the number of the
stained cells was lower in the neoplastic cells. No staining
was observed in normal brain (Fig. 1A and B). The
specificity of the reaction was confirmed by the absence of
staining when glioblastoma samples were stained with
antibodies pre-incubated with the peptide against which anti-
bodies were raised (Fig. 1F). There was no staining in the
absence of the primary antibodies (data not shown).
Conversely, a positive nuclear staining was present in the
same glioblastoma immunostained with the HMGA1 anti-
body (Fig. 1E).
RT-PCR analysis of the hmga1 gene expression. To validate
the immunohistochemical data and to objectively compare
the level of hmga1 expression, 3 representative normal brain
tissues, 3 astrocytomas and 3 glioblastomas were also analysed
by RT-PCR using hmga1 specific primers. The relative
expression levels of hmga1 mRNA to ß-actin which was used
as an internal control were calculated. The resulting values
were normalized versus normal tissue, which received the
value of 1. The results are shown in Fig. 2. The RT-PCR data
essentially confirmed the immunohistochemical results. In
fact, the relative expression level of hmga1 was increased
(2.24-fold) in astrocytomas in comparison to the normal brain.
The increase in hmga1 expression level was even higher
(5.58-fold) in glioblastoma, thus supporting the immuno-
histochemical findings that suggest that an increased hmga1
expression correlates with the tumour aggressiveness.
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Figure 1. HMGA1 immunostaining in normal brain, astrocytoma and glioblastoma. Paraffin sections from normal brain (A,B), astrocytoma (C), and
glioblastoma (D,E), were analyzed by immunohistochemistry using antibodies raised against a specific HMGA1 peptide. As a negative control (F),
glioblastoma immunostained with HMGA1 antibodies pre-incubated with the peptide against which antibodies were raised, no immunoreactivity was
observed. Magnification, x40.
Discussion
Glioblastoma is one of the most aggressive tumors in mankind
with 50% of patients dying within the 1st year of diagnosis,
and being refractory to conventional therapies (17,18,20).
Therefore, it may represent an excellent target for new
therapeutic approaches, and the search for new molecular
targets might be a useful means to approach an innovative
therapy for this kind of neoplasia.
HMGA1 expression, abundant during embryonic
development, is low or absent in normal adult tissues (7,24),
whereas its induction represents a common feature of malignant
tumors. Indeed, in the 1980s elevated expression of HMGA1
protein was found to be associated with the acquisition of a
highly malignant phenothype in rat thyroid transformed cells
and in thyroid and skin experimental tumors (13-15).
Subsequently, HMGA1 proteins were detected in human
thyroid (8,10), colon (2,9,11), prostate (23), cervix (3), and
pancreatic (1) carcinomas, but not in normal counterpart
tissues.
Therefore, the present study tested whether HMGA1
product is expressed in astrocytic tumors and whether there is
a correlation between tumoral progression and expression of
this gene. Here we report the analysis of the HMGA1
expression in 12 astrocytomas and 15 glioblastomas. Positive
staining was observed in all the tumors, however the number
of the stained cells and intensity of staining was more elevated
in glioblastomas. RT-PCR results confirmed the immuno-
histochemical data. 
Therefore, given the fact that increased expression level
of HMGA1 protein is closely associated with the malignant
phenotype, determination of the HMGA1 expression level
could be used as a diagnostic marker in the pathology of
these tumors. These results are consistent with previous data
in colon and cervical carcinomas where it has been shown
that an increase in HMGA1 levels correlate with malignancy
grade (2,3,9).
It has been demonstrated that overexpression of the
HMGA1 proteins is causally associated with both neoplastic
transformation and metastatic progression. In fact, the block
of HMGA1 synthesis prevents rat thyroid cell transformation
by murine transforming retroviruses and an adenovirus carrying
the hmga1 gene in antisense orientation induced cell death in
thyroid anaplastic carcinoma cells (4,5). Therefore, we could
envisage a therapy based on the suppression of the HMGA1
protein function also in glioblastoma, expecially if associated
with surgical therapy. Studies are in progress in our laboratory
to evaluate this possibility. 
In conclusion, on the basis of these findings, we propose
that HMGA1 proteins could play an important role in a multi-
stage process of carcinogenesis of astrocytic tumors and that
the HMGA1 protein level could serve as a potential diagnostic
marker, which may enable the identification of tumor cells
with potential to be biologically malignant, and as a potential
target for gene therapy of human glioblastoma tumors.
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HMGA1 (high-mobility-group A1) proteins are architectural tran-
scription factors that are found overexpressed in embryogenesis
and malignant tumours. We have shown previously that they have
a role in lymphopoiesis, since the loss of HMGA1 expression
leads to an impairment of T-cell development and to an increase in
B-cell population. Since RAGs (recombination activating genes)
are key regulators of lymphoid differentiation, in the present study
we investigate whether RAG2 expression is dependent on
HMGA1 activity. We show that RAG2 gene expression is up-regu-
lated in Hmga1−/− ES (embryonic stem) cells and EBs (em-
bryoid bodies) as well as in yolk sacs and fibroblasts from
Hmga1−/− mice, suggesting that HMGA1 proteins control RAG2
gene expression both in vitro and in vivo. We show that the effect of
HMGA1 on RAG2 expression is direct, identify the responsible
region in the RAG2 promoter and demonstrate binding to the
promoter in vivo using chromatin immunoprecipitation. Since
RAG2 is necessary for lymphoid cell development, our results
suggest a novel mechanism by which HMGA1 might regulate
lymphoid differentiation.
Key words: electrophoretic mobility-shift assay (EMSA), em-
bryonic stem cell, high-mobility-group A1 (HMGA1), lympho-
poiesis, MEF, recombination activating gene 2 (RAG2).
INTRODUCTION
HMGA1 (high-mobility-group A1) proteins are ‘architectural
transcription factors’ capable of binding the minor groove of AT-
rich DNA sequences and inducing the bending of DNA inter-
mediates. HMGA1 proteins have been found overexpressed in
many kinds of human malignancies and rearranged in benign
tumours [1]. They seem to play a major physiological role during
development and cell differentiation [1]. We showed previously
that HMGA1 proteins play a pivotal role in lymphocyte differ-
entiation [2]. In particular, we suggested that the loss of Hmga1
gene expression might force the B-cell/T-cell common lymphoid
precursor to differentiate to B-lymphocytes rather than to T-lym-
phocytes, probably by regulating the expression levels of cyto-
kines involved in B- and T-cell proliferation/differentiation. In
fact, the loss of HMGA1 induces a decrease in interleukin-2
expression and an increase in interleukin-6 expression both in vitro
and in vivo [2] (M. Fedele, V. Fidanza, S. Battista, F. Pentimalli,
A. J. P. Klein-Szanto, R. Visone, I. De Martino, A. Curcio,
C. Morisco, L. Del Vecchio, G. Baldassarre, C. Arra, G. Viglietto,
C. Indolfi, C. M. Croce and A. Fusco, unpublished work). More
strikingly, the lack of HMGA1 in homozygous knockout mice
leads to the development of different B-cell neoplasias (M. Fedele
et al., unpublished work), probably due to the alteration in B-cells/
T-cells balance.
To investigate further the molecular mechanisms involved in
HMGA1 regulation of lymphopoiesis, we analysed the expression
of RAGs (recombination activating genes). RAG1 and RAG2 are
key performers of the V(D)J recombination, through which the
specific antigen receptors in lymphocytes are generated [3,4]. In
particular, they initiate the process of recombination, introducing
double-strand breaks in target sequences of the Ig and T-cell
receptor genes. In the absence of either RAG1 or RAG2 gene pro-
duct, the development of mature lymphocytes is completely abro-
gated, leading to immunodeficiency, both in mouse and humans
[5–7]. On the other hand, to limit recombinase activity, their
expression is tightly regulated both at the transcriptional and
post-transcriptional levels [8,9]. At the transcriptional level, the
alteration of chromatin structure in the 5′-region of RAG1 and
RAG2 genes has been shown to be responsible for their tissue-
and stage-specific regulation [10,11]. The RAG2 promoter is dif-
ferently regulated in B- and T-cells [12]. Moreover, in the RAG2
promoter region, a 300 bp 5′-upstream region from the major
transcription initiation site is conserved between mice and humans
[12], indicating that this region is important for the promoter
activity. Human RAG2 promoter has been shown to be activated
both in lymphoid and non-lymphoid lineages [13]. A core pro-
moter of mouse RAG2 confers lymphoid specificity and may
be regulated by distinct transcription factors in B- (Pax-5) and
T- (GATA-3 or c-Myb) cells [8,12,14]. It has been shown that the
LEF-1−β-catenin complex regulates the RAG2 promoter activ-
ation, together with c-Myb and Pax-5 in immature B-cells [9]. In
the present study, we report that lack of HMGA1 proteins, which
are known to regulate lympho-specific genes, is associated with
increased RAG2 expression in mouse ES (embryonic stem) cells.
RAG2 up-regulation is also found in yolk sacs and MEFs (mouse
embryonic fibroblasts) from Hmga1-null embryos. Conversely,
introduction of an Hmga1-expressing construct into Hmga1−/−
ES cells restores RAG2 gene expression at levels comparable with
wild-type ES cells. Functional assays demonstrate that HMGA1
proteins are capable of repressing the RAG2 promoter in 293T
cells and that the HMGA1 repressive activity is noticeably
Abbreviations used: c/EBP-β, CAAT/enhancer-binding protein β; CMV, cytomegalovirus; dpc, days post-coitum; EB, embryoid body; EMSA, electro-
phoretic mobility-shift assay; ES cell, embryonic stem cell; FBS, fetal bovine serum; HA, haemagglutinin; HMGA1, high-mobility-group A1; MEF, mouse
embryonic fibroblast; MTG, monothioglycerol; RAG, recombination activating gene; RT, reverse transcriptase.
1 To whom correspondence should be addressed, at Dipartimento di Biologia e Patologia Cellulare e Molecolare (email afusco@napoli.com).
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increased by co-expression of c/EBP-β (CAAT/enhancer-binding
protein β). Finally, we show that the repressive effect of HMGA1
on RAG2 promoter is due to a direct specific interaction of the
architectural factor with the RAG2 promoter in vitro and in vivo.
MATERIALS AND METHODS
Cell cultures
Wild-type, Hmga1+/− and Hmga1−/− AB2.1 ES cells have
been described in [2]. Hmga1−/−R and Hmga1−/−CMV (where
CMV stands for cytomegalovirus) clones were generated by elec-
troporating Hmga1−/− ES cells with 20 µg of pc-Hmga1/
Hygro construct or the empty vector respectively [2]. Transgene
expression was detected by Northern blotting and RT (reverse
transcriptase)–PCR. ES cells were cultured on a layer of myto-
micin D-inactivated fibroblasts. Before RNA extraction, fibro-
blasts were removed by three passages in 0.1% gelatin-treated
plates and the maintenance of the undifferentiated state was
ensured by the addition of leukaemia inhibiting factor (103 units/
ml; Chemicon, Temecula, CA, U.S.A.). MEFs were obtained from
12.5-day-old embryos. Cells were cultured at 37 ◦C (5% CO2)
in Dulbecco’s modified Eagle’s medium containing 10% (v/v)
FBS (fetal bovine serum) supplemented with penicillin and
streptomycin. The human embryonic kidney 293T cell line [14]
was cultured in Dulbecco’s modified Eagle’s medium + 10%
FBS.
Differentiation of ES cells
Differentiation of ES cells in a methylcellulose-based medium
has been described in [2]. Briefly, 48 h before differentiation,
2 × 105 ES cells were plated on gelatin-coated plates in Iscove’s
modified Dulbecco’s medium supplemented with 15% FBS,
sodium pyruvate (1 mM), L-glutamine (2 mM) and non-
essential amino acids (0.1 mM; Gibco BRL, Life Technologies,
Gaithersburg, MD, U.S.A.), MTG (monothioglycerol; 100 µM;
Sigma), leukaemia inhibiting factor (10 ng/ml; Chemicon),
penicillin G and streptomycin. Materials for differentiation were
purchased from Stem Cell Technologies (Vancouver, BC, U.S.A.)
unless otherwise specified. To obtain EBs (embryoid bodies),
2 × 103 ES cells were plated on low-adherence 35 mm Petri dishes
as a single cell suspension in ‘primary differentiation medium’,
constituted by 0.9% methylcellulose in Iscove’s modified
Dulbecco’s medium, 15% FBS, L-glutamine (2 mM), MTG
(150 µM) and murine stem cell factor (40 ng/µl). Feeding me-
dium (0.5% primary differentiation medium, 15% FBS, 150 µM
MTG and 160 ng/ml murine stem cell factor) was added after
7 days in culture and subsequently every 3–4 days.
Generation of Hmga1+/− and Hmga1−/− mice
Hmga1+/− and Hmga1−/− mice have been described in [2].
Briefly, Hmga1+/− ES cell clones were microinjected into
3.5 dpc (days post-coitum) C57BL/6J blastocysts and reimplanted
into foster mothers (the Animal Facility in Thomas Jefferson Uni-
versity). Chimaeric mice were crossed with wild-type and some
of them gave germline transmission. Single knockout mice were
then intercrossed to obtain double knockout mice. Pregnant
mothers were killed at 14.5 dpc and the embryo genotype was
evaluated [2].
RT–PCR analyses of embryos, MEFs and ES cell cultures
Tissues from mice were rapidly dissected, frozen on solid CO2 and
stored at −80 ◦C. Total RNA from embryos and cell cultures was
extracted with TRI Reagent solution (Molecular Research Center,
Cincinnati, OH, U.S.A.) according to the manufacturer’s instruc-
tions and treated with DNase I (GenHunter Corporation,
Nashville, TN, U.S.A.). RNA (1 µg) was reverse-transcribed
using a mixture of poly-dT and random exonucleotides as primers
and MuLV RT (PerkinElmer, Boston, MA, U.S.A.). PCR ampli-
fications were performed as described in [15] in a GeneAmp PCR
System 9600. Primers for RAG2, Hmga1 and Gapdh have been
described in [2,16]. Non-reverse-transcribed RNA was ampli-
fied (results not shown) to rule out the possibility of DNA
amplification. The PCR products were separated on 2% (w/v)
agarose gel and, if necessary, blotted and hybridized with specific
probes.
Plasmids
The pc-Hmga1/Hygro and pCEFL/HA-HMGA1 constructs
(where HA stands for haemagglutinin) have been described in
[2,17]. For the RAG2prom-luc construct, the region −279/+21
of the mouse RAG2 gene [12] was amplified using the following
primers: forward primer, 5′-ACGCGTAAGCTTAAGACAGTC-
ATT-3′, containing an MluI restriction site, and reverse primer, 5′-
CTCGAGCTGAAGGCTGCAGGGTAG-3′, containing an XhoI
restriction site. The resulting fragment was subcloned into the
pGL3 vector (Promega, Madison, WI, U.S.A.). C/EBP-β ex-
pression vector has been described in [17].
Production of recombinant proteins
Production of the recombinant HMGA1b–His protein has been
described in [18]. Recombinant HMGA1b(1–53) is constituted by
the first 53 amino acids spanning the first two AT-hook domains,
whereas HMGA1b(54–96) contains the spacer region between the
second and third AT-hook, the third AT-hook domain and the C-
terminal region of the protein. The recombinant HMGA1 pro-
teins were generated by cloning the full-length or truncated
Hmga1b cDNAs in the pET2c (Novagen, Madison, WI, U.S.A.).
BL21/DE3 cells transformed with each vector were grown in
Luria–Bertani medium, induced with isopropyl β-D-thiogalacto-
side, sonicated and purified by using the His-Trap purification
kit (Amersham Biosciences) according to the manufacturer’s
instructions. The proteins were dialysed and analysed by SDS/
12.5% PAGE.
EMSA (electrophoretic mobility-shift assay)
DNA-binding assays with the recombinant proteins were per-
formed as described previously [19]. Briefly, 5 (14 nM) to 50 ng of
wild-type recombinant protein or 5 ng of truncated proteins were
incubated with radiolabelled double-strand oligonucleotides, cor-
responding to the region spanning bases 14–53 of the murine
RAG2 promoter region (RAG2pr) (NCBI accession no.
AF159439). The full-length protein was also assayed with trunc-
ated or mutated oligonucleotides (Figure 2B) representing differ-
ent AT-rich segments of the RAG2pr region. For EMSA on mouse
spleens, 8 µg of protein extracts from wild-type, Hmga1+/−
and −/− adult spleens were incubated in a solution made up
of 20 mM Hepes (pH 7.6), 40 mM KCl, 0.1 mM EDTA, 0.5 mM
MgCl2, 0.5 mM dithiothreitol, 0.1 mM PMSF, 1 µg of poly(dC-
dG), 2 µg of BSA and 10% (v/v) glycerol to a final volume of
20 µl for 10 min at room temperature (25 ◦C). The samples were
incubated for 10 min after the addition of 2.5 fmol of a 32P-end-
labelled oligonucleotide (specific activity, 8000–20000 c.p.m./
fmol). In some experiments, a 100-fold molar excess of unlabelled
oligonucleotide was added as a specific competitor. For antibody
competition analyses, extracts were preincubated with 0.5 µg of
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anti-HMGA1 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, U.S.A.) or an unrelated antibody (anti-Pit-1; Santa Cruz Bio-
technology) on ice for at least 30 min. The Sp1 oligonucleotide
was purchased from Santa Cruz Biotechnology. The DNA–pro-
tein complexes were resolved on 6% (w/v) non-denaturing acryl-
amide gels and visualized by exposure to autoradiographic films.
Chromatin immunoprecipitation
Briefly, approx. 3 × 107 wild-type, Hmga1+/− and Hmga1−/−
ES cells were grown on 75 cm2 dishes. Chromatin immuno-
precipitation was performed as described in [2,20] using anti-
bodies binding to the N-terminal region of the HMGA1 proteins
[21] and not reactive to other members of the HMGA family.
Input DNA (500 ng) and immunoprecipitated DNAs were ana-
lysed by PCR for the presence of RAG2 promoter sequences or
the prolipase promoter region, as negative control. PCRs were
performed with AmpliTaq gold DNA polymerase (PerkinElmer).
The primers used to amplify the sequence of RAG2 promoter
were: forward, 5′-AAGCTTAAGACAGTCATT-3′; and reverse,
5′-CTGAAGGCTGCAGGGTAG-3′. Primers for prolipase pro-
moter were: forward, 5′-ACCAAAGTGTCAAGGGCAAC-3′;
and reverse, 5′-ATTCCCTAAACCCAGCATCC-3′. PCR pro-
ducts were resolved on a 2% agarose gel, stained with ethidium
bromide and scanned using a Typhoon 9200 scanner.
Transient transfections
Before transient transfections in ES cells, feeder fibroblasts were
removed as described above. A total of 4 × 105 wild-type or
double knockout ES cells or 293T cells were plated on 6-well
plates and transfected after 48 h with 1 µg of reporter plasmid
(either RAG2prom-luc or pGL3), by FuGene6 (Roche,
Indianapolis, IN, U.S.A.). Where indicated, 3 µg of HA–Hmga1
and/or 3 µg of c/EBP-β were co-transfected. Cells were harvested
48 h post-transfection and lysates were analysed for luciferase
activity. Transfection efficiency was normalized using the β-gal-
actosidase activity, and fold activation was calculated by dividing
by pGL3 luciferase activity. All the assays were performed in
triplicate and repeated in three independent experiments.
RESULTS
Loss of HMGA1 is correlated with an increased RAG2 expression
in ES cells
We previously generated Hmga1−/− mouse ES cells and showed
that their ability to differentiate in lymphohaematopoietic lineages
is greatly compromised [2]. In particular, we showed that the
T-cell population is decreased, whereas the B-cell population is
increased in Hmga1−/− ES cells, yolk sacs and fetal livers com-
pared with wild-type. To investigate further the role that HMGA1
proteins play in B-cell/T-cell differentiation, we analysed the
expression of RAG2, a lymphoid-specific gene, by RT–PCR ana-
lyses. As shown in Figure 1(A), we detected an 8-fold increase in
RAG2 expression in Hmga1−/− ES cells compared with wild-
type and single knockout ES cells and a 2.5-fold increase in ES
cell-derived Hmga1−/− EBs compared with wild-type (lanes 6
and 7). No band was detected when the RNA was not reverse-
transcribed before amplification (results not shown).
To verify that the lack of HMGA1 was responsible for RAG2
up-regulation, we transfected the pc-Hmga1/Hygro construct in
double knockout ES cells [2]. We verified the rescue of Hmga1
expression in some clones (−/−R1) by RT–PCR (Figure 1A).
A decreased RAG2 expression was observed in Hmga1-trans-
fected cells (−/−R1) compared with Hmga1 null cells and
Figure 1 RAG2 expression in wild-type and Hmga1 knockout ES cells, EBs,
yolk sacs and MEFs
RT–PCR analyses for RAG2 and Hmga1 expression were performed on RNA extracted from
(A) ES cells and EBs; (B) yolk sacs (YS); and (C) MEF. Gapdh expression was evaluated as
internal control. −/−CMV and −/−R1 indicate Hmga1−/− ES cells transfected with the
empty vector and with the pc-Hmga1-expressing construct respectively.
Hmga1−/− cells transfected with the empty vector (−/−CMV)
(compare lanes 3, 4 and 5 in Figure 1A). These results suggest that
HMGA1 proteins regulate RAG2 gene expression in ES cells and
in ES cell-derived EBs. Moreover, when the mammary epithelial
cells MCF-7 were stably transfected with the Hmga1/Hygro con-
struct (results not shown), the expression of RAG2 was down-
regulated, suggesting that HMGA1 proteins induce RAG2
down-regulation in different cell types.
Loss of HMGA1 determines up-regulation of RAG2 gene
expression in vivo
We next investigated RAG2 expression in vivo. We analysed
RAG2 expression in 14.5 dpc yolk sacs from wild-type,
Hmga1+/− and −/− embryos. As shown in Figure 1(B), RAG2
expression was sensibly higher in Hmga1-null and heterozygous
yolk sacs, compared with wild-type. RT–PCR analyses for Hmga1
expression were performed as a control of the genotype of the
tissues analysed (Figure 1B, middle panel). Moreover, RAG2
overexpression was observed also in the spleen from Hmga1−/−
adult mice, compared with wild-type (M. Fedele et al., un-
published work), indicating that HMGA1 affects RAG2 expres-
sion both in vitro and in vivo. Next, we investigated whether
lack of HMGA1 affects RAG2 expression in non-lymphoid cells.
Again, RAG2 expression in MEFs from wild-type, Hmga1+/−
and −/− embryos was inversely related to HMGA1 expression
(Figure 1C).
These results indicate that RAG2 expression is inversely related
to Hmga1 expression both in vitro and in vivo, suggesting a sup-
pressive role for the HMGA1 proteins in the regulation of RAG2
transcription.
HMGA1 proteins directly bind the RAG2 promoter
To investigate whether HMGA1 proteins are directly involved in
RAG2 transcriptional regulation, we evaluated the HMGA1 DNA-
binding activity to the RAG2 promoter. In particular, we analysed
a region spanning nt 14–53 of the murine RAG2 promoter
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Figure 2 HMGA1 binding to RAG2 upstream regulating region
(A) EMSA was performed by incubating the radiolabelled wild-type RAG2 promoter oligonucleotide (RAG2pr) with 5 ng (lanes 1 and 4), 20 ng (lane 2) or 50 ng (lane 3) of the recombinant full-length
HMGA1b–His protein or with 5 ng of truncated HMGA1b(1–53) (lanes 6 and 7) or HMGA1b(54–96) (lanes 8 and 9) proteins. Where indicated, a 100 times molar excess of unlabelled RAG2pr
oligonucleotide was incubated as a specific competitor. (B) Sequences of RAG2 promoter oligonucleotides used in electrophoretic binding assays. Hypothetical HMGA1-binding sites are boxed in
grey. WT, the wild-type sequence. Oligonucleotides A–C are shorter wild-type sequences, encompassing a few hypothetical HMGA1-binding regions. In oligonucleotides D and E, some nucleotides
were mutated (underlined). (C) EMSA was performed with deleted or mutated oligonucleotides. The probes used (A–E) are the same as in (B). Full-length HMGA1b–His protein (5 ng) was incubated
with the indicated probes (A–E) in the presence (+) or absence (–) of a 100 times molar excess of the corresponding unlabelled oligonucleotides, as specific competitor. (D) EMSAs were performed
by incubating 8 µg of protein extracts from wild-type (wt), Hmga1+/− and −/− mouse spleens with the RAG2pr probe. Where indicated, the samples were preincubated either with anti-HMGA1
(α-HMGA1) or unrelated antibodies [anti-Pit-1 (α-Pit-1)] or with a 100 times molar excess of unlabelled RAG2pr. Two main specific complexes, corresponding to isoforms a an b of HMGA1, were
observed in wt and Hmga1+/− extracts, whereas no binding activity was detected in Hmga1−/− extracts. (E) EMSA was performed with the same extracts as in (D), incubated with a probe
corresponding to the Sp1 consensus sequence to normalize the amount of protein extracts.
[12] (Rag2pr) and containing four AT-rich putative HMGA1-bind-
ing sites (Figure 2B). As shown in Figure 2(A), increasing
amounts (5, 20 and 50 ng) of a recombinant HMGA1 protein [18]
were capable of binding the 32P-end-labelled double-strand oligo-
nucleotide in EMSA. This binding was specific, as demonstrated
by competition with 100-fold molar excess of unlabelled RAG2pr
oligonucleotide (lane 4) and by lack of competition when an
unrelated unlabelled oligonucleotide was used as competitor
(results not shown). To evaluate the regions of HMGA1 proteins
involved in binding to the RAG2 promoter, we performed EMSAs
by incubating 5 ng of truncated recombinant HMGA1 proteins
with the RAG2pr probe. We demonstrated that the HMGA1 DNA-
binding activity is due to the first two AT-hook domains, since
HMGA1b(1–53), containing the first two AT-hook domains, was
capable of binding RAG2pr, whereas HMGA1b(54–96), contain-
ing the spacer region between the second and third AT-hook, the
third AT-hook domain and the C-terminal region of the protein
was not (compare lanes 6 and 8). To map better the preferential
HMGA1-binding sites on the RAG2 promoter, we assayed three
shorter oligonucleotides, oligos A–C (Figure 2B), representing
three different AT-rich segments of the RAG2 promoter. As shown
in Figure 2(C), HMGA1 binds oligo B with high affinity,
whereas the binding to oligos A and C is almost undetectable
(lanes 1 and 5). Binding specificity was demonstrated by com-
petition experiments after the addition of a 100-fold molar excess
of unlabelled oligo B (lane 4). These results restrict the HMGA1-
binding region to the central part of the sequence, which retains
three of four putative HMGA1-binding sites (TTTT, AAAA and
TTT). To identify which site is responsible for the binding,
we mutated the A-stretch region (oligo D): we found that the
HMGA1 protein was no longer able to bind the sequence (lane 7),
demonstrating that the A-stretch is important for the binding.
On the other hand, when the downstream T-stretch was mutated
(oligo E), the A-stretch was not sufficient to carry on the binding
(lane 9), showing that both the A-stretch and the downstream
T-stretch are necessary for the binding (Figure 2C). Conversely,
the upstream T-stretch does not consistently co-operate with the
A-stretch for the binding, since oligo E contains both the upstream
T- and A-stretches, but does not show a significant binding to
HMGA1.
To verify the binding of HMGA1 to RAG2 promoter also in
mouse tissues, we assayed the DNA-binding activity of total pro-
tein extracts from spleens of wild-type, heterozygous and knock-
out mice to the RAG2pr probe. As shown in Figure 2(D), two
specific complexes, with a mobility corresponding to isoforms a
and b of HMGA1 proteins, were present in extracts from both
wild-type and heterozygous spleens, whereas they were absent
from extracts derived from homozygous Hmga1 knockout
spleens. These complexes were specifically displaced by incu-
bation with an antibody directed against the HMGA1 proteins
(compare lanes 3 and 1), but not by an unrelated antibody (lane 4),
showing that they do consist of HMGA1 proteins. Binding activity
was normalized using an oligonucleotide probe for the ubiquitous
Sp1 transcription factor (Figure 2E).
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Figure 3 In vivo binding of HMGA1 proteins to the RAG2 promoter region
Chromosomes and nuclear proteins from Hmga1+/+, +/− and −/− ES cells were cross-
linked and immunoprecipitated (IP) with anti-HMGA1 antibodies. The presence of the −279/
+21 sequence of the RAG2 promoter was detected by PCR. INPUT indicates PCR products with
chromosomal DNA without immunoprecipitation. As an immunoprecipitation control, IgG was
used (lane 7). The lower panel shows PCR amplification of the immunoprecipitated DNA using
primers for the prolipase gene promoter.
In conclusion, these results indicate that HMGA1 proteins are
capable of binding directly a specific sequence in the RAG2 pro-
moter region and that the normal spleens contain a binding activ-
ity that is lost in Hmga1−/− spleens.
To verify whether HMGA1 proteins bind the −297/+21 RAG2
promoter region in vivo, we performed chromatin immuno-
precipitation experiments in Hmga1+/+, +/− and −/− ES cells
(Figure 3). Anti-HMGA1 antibodies precipitated the −297/+21
RAG2 promoter region from Hmga1+/+ and +/− ES cells, but
not from Hmga1−/− ES cells (Figure 3). The RAG2 promoter
was immunoprecipitated by anti-HMGA1 antibodies, whereas
no precipitation was observed with normal rabbit IgGs (lane 7);
moreover, when primers for a control promoter (prolipase) were
used, no band was detected (Figure 3, lower panel), suggesting
that the reaction is specific for the RAG2 promoter. The results
indicate that HMGA1 proteins bind the RAG2 promoter region
in vivo.
HMGA1 proteins repress RAG2 promoter activity in functional
assays
To investigate the effect of HMGA1 proteins on RAG2 promoter,
we transiently transfected wild-type and double knockout ES cells
with a construct (RAG2prom-luc) expressing the luciferase gene
under the control of the mouse RAG2 promoter region, −279 to
+21. The region spanning −279 to +123, conserved between
mice and humans, has been shown to be necessary for maximal
activity of RAG2 promoter [12]. As shown in Figure 4(A),
Hmga1−/− ES cells showed a 2-fold increase in RAG2 promoter
activity compared with wild-type.
We next transfected 293T cells with the RAG2prom-luc re-
porter construct. As observed previously [12], the promoter
showed extremely low but reproducible activity in non-lymphoid
cell lines, such as 293T. However, when the HMGA1 expression
vector was transfected, a decrease in the luciferase activity was
observed (Figure 4B). We showed previously that c/EBP-β co-
operates with HMGA1 in activating the leptin gene promoter [17]
by direct interaction with HMGA1. At least two binding motifs for
c/EBP-β are present in the promoter region of the human RAG2
gene (at −146 to −138 and at −137 to −129) and mutations
in the −137 to −129 region abrogate promoter activity [22]. In
the mouse RAG2 promoter, a c/EBP-β consensus sequence is loc-
ated at −154 to −146. To evaluate whether c/EBP-β and HMGA1
co-operate in regulating RAG2 promoter activity, we co-trans-
fected a construct expressing c/EBP-β together with the HMGA1
expression construct: the co-transfection of c/EBP-β, together
with Hmga1, induced a further decrease of luciferase activity
(Figure 4B), whereas c/EBP-β by itself induced just a slight
decrease.
These results indicate that HMGA1 proteins negatively regulate
the RAG2 promoter in different cell types and that c/EBP-β
is capable of co-operating with HMGA1 in repressing RAG2
expression.
DISCUSSION
The aim of the present study was to investigate the role of HMGA1
proteins in the regulation of RAG2 gene expression. The rationale
for this study was our previous observation that disruption of the
Hmga1 gene leads to alterations of lymphopoiesis [2].
The results presented here demonstrate that Hmga1−/− ES
cells express higher levels of RAG2 and that increased RAG2 ex-
pression also occurs in MEFs and yolk sacs of Hmga1−/− mice.
The increase in RAG2 expression is due to the lack of HMGA1
proteins, since the introduction of an Hmga1-expressing construct
brings RAG2 expression to levels comparable with wild-type ES
Figure 4 Functional assays of RAG2 promoter activity
Luciferase activity (fold activation) of RAG2 promoter in Hmga1+/+ and −/− ES cells (A) and in 293T cells (B). Where indicated, 3 µg of HMGA1 and/or 1 µg of c/EBP-β expression vectors were
co-transfected.
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cells. In support of this statement, we show that the HMGA1
proteins bind to the RAG2 promoter, in vitro and in vivo, by
EMSA and chromatin immunopreciptiation assays respectively.
This suggests a direct regulation of RAG2 by HMGA1. We con-
clude that the binding is mediated by two specific A and T adjac-
ent stretches on the RAG2 promoter and by the first two AT-hook
domains of the HMGA1 proteins. Moreover, we demonstrate that
an HMGA1-expressing construct is capable of repressing the
activity of a RAG2 promoter-driven luciferase gene in functional
assays. We also show that the HMGA1 repressive activity is in-
creased by the co-expression of c/EBP-β, a transcription factor
already known to co-operate with HMGA1 in the regulation of
other promoters [17] and possibly affecting human RAG2 pro-
moter activity [22]. The slight decrease in gene expression, exerted
by HMGA1 in transient transfections, matches with transient
assays on other HMGA1-responsive promoters, where the light
stimulating effect of HMGA1 is potentiated by co-operating
transcription factors [23,24]. Together, these results demonstrate
that HMGA1 proteins down-regulate RAG2 expression. On the
other hand, the repressive activity of HMGA1 proteins on RAG2
promoter does not seem to be exerted through the down-regu-
lation of other factors involved in RAG2 transcription such as
Pax-5, c-Myb and GATA-3, since their expression is unchanged
in Hmga1−/− ES cells compared with wild-type (results not
shown). Since RAG2 plays a major role in B-cell/T-cell differen-
tiation, the HMGA1-mediated down-regulation of RAG2 ex-
pression suggests a possible mechanism by which loss of HMGA1
expression may lead to an impairment of lymphoid differentiation
in vitro.
Given the role of architectural transcription factor ascribed to
HMGA1 (capable of recognizing the DNA structure rather than
sequence), a probable mechanism by which HMGA1 proteins
exert their action on the RAG2 promoter might be in opening the
chromatin structure of RAG2 promoter region and improving
its accessibility to appropriate transcriptional factors. Similar
mechanisms have been already described for transcriptional
regulation of the RAG1 gene [10]. Consistent with our findings, it
has been recently reported that another member of the HMG-box
family, LEF-1 (lymphoid enhancer-binding factor-1), binds the
−41/−17 RAG2 promoter region and, together with c-Myb and
Pax-5, is capable of activating the RAG2 promoter [9].
The negative regulation of RAG2 by HMGA1 might have quite
important implications since an increased RAG2 expression may
induce a higher V(D)J recombination and, in the absence of an
appropriate cell-cycle checkpoint, lead to increased susceptibility
to develop neoplasias of the lymphoid tissues. RAG proteins may
also mediate the insertion of cleaved recombination signals into
new DNA sites [25] and this mechanism has been proposed to be
responsible for certain types of DNA translocation associated with
lymphatic tumours. Interestingly, Hmga1−/− mice develop B-
cell lymphomas, characterized by a high frequency of aberrant
V(D)J rearrangements in the IgH gene (M. Fedele et al.,
unpublished work).
Since RAG2 activates double-strand breaks, our results suggest
that HMGA1 proteins may have an indirect role in regulating pro-
cesses such as double-strand breaks and recombination. We pre-
viously showed that HMGA1 is inherently involved in the down-
regulation of the DNA repair protein BRCA-1 [20] and that this
function is converted into a greater ability of Hmga1−/− ES cells
to repair cisplatinum-induced DNA breaks [26]. On the other
hand, HMGA1 can bind a fourway (Holliday) junction DNA, an
intermediate structure formed by DNA during recombination pro-
cesses [27,28], competing for its binding with histone H1 and
HMG1 [29]. Consistently, a possible involvement of HMGA1 in
in vivo processes such as genetic recombination, DNA repair
and chromosome rearrangements have been proposed [28].
Together, these observations suggest that HMGA1 might have
a specific and pleiotropic role at different steps of DNA break
repair and recombination. Other than an indirect role (such as
down-regulation of BRCA1 and RAG2), it might play a direct
role in binding and bending of DNA, allowing the apposition of
sequences to be recombined.
It has been shown that inactivating mutations in either RAG1
or RAG2 are responsible for the so-called ‘Omen syndrome’, in
which no circulating mature B-cells are found, while a large num-
ber of poorly functional T-lymphocytes could be detected [30].
Conversely, overexpression of RAG proteins may contribute to
some cases of human immunodeficiency [31] and lymphocytic
leukaemia. Interestingly, Hmga1-null mice develop B-cell lym-
phomas (M. Fedele et al., unpublished work), whereas those
overexpressing the full-length construct develop T-cell lympho-
mas [18]. Therefore it can be hypothesized that the impairment
of the HMGA1 function might be responsible for some cases of
human immunodeficiency.
In conclusion, the results presented here demonstrate that
HMGA1 down-regulates the RAG2 promoter and suggest an
additional mechanism for the modulation of lymphopoiesis by
HMGA1 proteins.
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2ABSTRACT
HMGA1 proteins play their major physiological role during embryonic
development and have a critical role in neoplastic transformation. Here, we
show that the Hand1 gene, which codes for a transcription factor crucial for
differentiation of trophoblast giant cells and heart development, is up-
regulated in hmga1 minus Embryonic Stem cells. Consistently with these
results, we were able to demonstrate that HMGA1 proteins bind directly to
Hand1 promoter in vitro and in vivo resulting in the inhibition of the Hand1
promoter activity. Since the HMGA1 proteins are over-expressed in
malignant neoplastic tissues, we have also investigated Hand1 expression in
human thyroid carcinoma cell lines and tissues: an inverse correlation was
found between HMGA1 and Hand1 expression. Since the down-regulation
of the Hand1  gene expression was not associated neither to loss of
heterozygosity nor to alteration of the methylation pattern, it is reasonable to
hypothesize that HMGA1 over-expression may play a critical role in Hand1
silencing. Finally, we show that the restoration of the Hand1 induces a
significant reduction in the growth rate of two thyroid carcinoma cell lines
suggesting a role of the Hand1 down-regulation in the process of thyroid
carcinogenesis.
3INTRODUCTION
The high-mobility group A (HMGA) protein family includes HMGA1a and
HMGA1b, which are encoded by hmga1 through alternative splicing (1
Johnson), and the closely related HMGA2 protein (2 Manfioletti). These
proteins are non-histone architectural nuclear factors, that bind the minor
groove of AT-rich DNA sequences through three short basic repeats, called
‘‘AT-hooks’’, located at the NH2- terminal region of the proteins. The
involvement of HMGA proteins in embryogenesis, cell proliferation,
differentiation, apoptosis and, above all, cancer development has been
extensively demonstrated (3 Reeves, Fedele carcinogenesis). HMGA1
proteins seem to play their major physiological role during embryonic
development (4 Thanos), in fact, HMGA1 expression is very high during
embryogenesis, whereas it is negligible in normal adult tissues. The
generation of hmga1 null mice unveiled a critical role of these proteins on
cardiomyocytic cell growth: in fact, both heterozygous and homozygous
mice for the hmga1-null allele showed cardiac hypertrophy, moreover, these
mice also developed hematologic malignancies, including B cell lymphoma
and myeloid granuloerythroblastic leukemia (6 Fedele 06).
HMGA1 proteins has been found abundant in several tumor cells, including
colorectal, prostate, thyroid, cervical, lung, glioma (Donato), and thyroid,
and the protein level is correlated to the increasing degree of malignancy or
metastatic potential (3).
We identified HMGA1-regulated genes analyzing by microarrays the
expression profile of ES cells carrying two, one and no hmga1 functional
alleles (5 Martinez).  Among the genes showing an increased expression
with a higher fold change in the ES hmga1 minus cells in comparison to the
4wild type, therefore negatively regulated by the HMGA1, we focused our
attention on the Hand1 gene, because of its role in heart development.
H a n d 1  (also named eHand/Hxt/Thing1) and H a n d 2
(dHand/Hed/Thing2) belong to the Twist subfamily of Class B bHLH
transcription factors (8 Cross et al., 1995; Cserjesi et al., 1995; Hollenberg et
al., 1995; Srivastava et al., 1995 SCEGLIERE UNA DI QUESTE
REFERENCES). Hand genes are expressed in numerous tissues, including
the heart, lateral mesoderm and neural crest derivatives. In addition, Hand1
is expressed at high levels in extra-embryonic membranes, whereas Hand2 is
expressed at high levels in the deciduum and at lower levels in extra-
embryonic membranes. Both Hand genes are expressed in similar embryonic
tissues during development but often with complementary instead of
overlapping expression within the tissues (9 Dev & Disease 04 Cserjesi). Hand1
promotes giant cell differentiation and, when ectopically expressed in
trophoblast stem cells, is sufficient to promote giant cell differentiation. This
implies that suppressing Hand1 in the trophoblast stem cell compartment is
essential for normal placental development (Cross Placenta 2005). Embryos
carrying a homozygous mutation of Hand1 arrest at E7.5 with severe
abnormalities in differentiation of trophoblast giant cells (10 Riley et al.,
1998). Additionally, Hand1 has important functions in cardiac looping and
differentiation since failures in these processes were observed upon rescue of
the placental defect (11 Riley et al., 1998; Firulli et al., 1998). In humans,
Hand1 expression has been detected in trophoblast-like cells, the amniotic
epithelium and in adult heart tissue, suggesting that the protein may fulfill
similar functions (12 Gene 03  Knofler). Besides the importance of Hand1 in
cardiac function and development, a role of Hand1 in cell proliferation and
neoplastic transformation has been envisaged. In fact, the Hand1 gene has
5been reported down-regulated in human gastric,  (13 CR Ushijima),
pancreatic (14 Oncogene Ushijima) and ovarian carcinomas (15 …):
hypermethylation of some genes, including Hand1, seems account for gene
silencing in these neoplasias.
Here, we report that Hand1 is up-regulated in hmga1 minus Embryonic
Stem cells, and that HMGA1 proteins bind directly to Hand1 promoter in
vitro and in vivo resulting in the inhibition of the Hand1 promoter activity.
Moreover, we report that Hand1 gene expression is down-regulated, in
absence of gene hypermethylation, in human thyroid carcinoma cell lines
and tissues where the HMGA1 proteins are over-expressed. Finally, the
restoration of Hand1 expression inhibits the growth of thyroid carcinoma
cell lines suggesting a critical role of the down-regulation of Hand1
expression in thyroid carcinogenesis.
6MATERIALS AND METHODS
Plasmids
For the Hand1prom-luc construct, the region  -2424 – -2728  of the mouse
Hand1  gene was amplified using as primers gggatacacgaaggtcagtttt
(forward) and ctgagatcccagatcactca (reversed),  cloned in TA Cloning
Vector (Invitrogen) and subcloned in pGL3 (Promega) KpnI-XhoI cloning
site. The point mutations in the HMGA binding site of the Hand1 promoter
were generated using the QuikChange Mutagenesis Kit (Stratagene) in
accordance with the manufacture’s protocols. The primers used were
t a t t t t a a c t a a t t a G G t a a t a a c a g a g t c t c c t c c t g c c  ( f o r w a r d )  a n d
ggcaggaggagactctgttattaCCtaattagttaaaata (reversed). Point mutations are
shown in uppercase type. Hand1, HMGA1 and HMGA2 expression
plasmids were constructed by cloning the murine full-length cDNAs of
Hand1 or Hmga1b or Hmga2 into the mammalian expression vector
pcDNA3.1 (Invitrogen).
Cell culture and transfections
The generation and the culture of hmga1+/- and hmga1-/- Embryonic Stem
cells are described elsewhere (15 Battista). FRTL-5, FRTL-5-KiMSV and
FRTL-5–HMGA1as-KiMSV cells, and their culture conditions are reported
elsewhere (16 Berlingieri). Five x 105 FRTL-5 cells were plated in 6- well
plates and transfected after 48 hours with 1 µg of reporter plasmid (either
7Hand1prom-luc, Hand1promMUT-luc or pGL3), by Lipofectamine 2000
(Invitrogen). Where indicated, Hmga1 or Hmga2 were transfected. Cells
were harvested 24 hours post-transfection and lysates were analysed for
luciferase activity. Transfection efficiency was normalized using the β-
galactosidase activity and fold of activation were calculated by dividing for
pGL3 luciferase activity. All the assays were performed in triplicate and
repeated in three independent experiments.
Human thyroid primary culture and human thyroid carcinoma cell lines
(TPC-1, WRO, NPA, ARO, FRO, NIM 1, B-CPAP, FB-1, FB-2, Kat-4 and
Kat-18) are described elsewhere (17). For cloning efficiency assays N-PA,
FB-2 cells were either transfected with equal amounts of pCDNA3-Hand1 or
the corresponding empty vector. 48 h post-transfection of the plasmids 5x105
cells were plated on 10-cm dishes and cultured with medium supplemented
with G418 (Invitrogen) for selection of transfected cells. Colonies were
stained (1.5% glutaraldehyde and 0.06% methylene blue in Hanks’ balanced
salt solution (Invitrogen) and photographed.
Tissue samples
Neoplastic human thyroid tissues and normal adjacent tissue or the
controlateral normal thyroid lobe were obtained from surgical specimens and
immediately frozen in liquid nitrogen. Thyroid tumours were collected at the
Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Benite,
France. The tumour samples were stored frozen until RNA extractions were
performed. Tissues from hmga1 +/- and hmga1 -/- mice have been described
elsewhere (15).
8RNA extraction from tissues and cells
Tissues were snap-frozen in liquid nitrogen and stored at –80°C until use.
Total RNAs were extracted from tissues and cell culture using TRI
REAGENT® (Molecular Research Center INC) solution, according to the
manufacture’s instructions. The integrity of the RNA was assessed by
denaturing agarose gel electrophoresis (virtual presence of sharp 28S and
18S bands) and spectrophotometry.
Semiquantitative and quantitative RT-PCR
RNAs were treated with DnaseI (Invitrogen) and reverse-transcribed using
random exonucleotides as primers and MuLV reverse transcriptase (Perkin
Elmer). To ensure that RNA samples were not contaminated with DNA,
negative controls were obtained by performing the PCR on samples that
were not reversed-transcribed but otherwise identically processed. For
semiquantitative PCR, reactions were optimized for the number of cycles to
ensure product intensity within the linear phase of amplification. The PCR
products were separated on a 2% agarose gel, stained with ethidium bromide
and scanned using a Typhoon 9200 scanner. Digitized data were analyzed
using Imagequant (Molecular Dynamics). Quantitative PCR was performed
with SYBR® Green PCR Master Mix (Applied Biosystems) as follows: 95
°C 10 min and 40 cycles (95 °C 15 s  and 60 °C 1 min). Each reaction was
performed in duplicate. To calculate the relative expression levels we used
the 2-DDCT method ( 18 Kenneth et al 2001). The primers sequences are:
murine F gatgccttctcgagttaaaa and R aagtgtagcgacaagaagga, rat F
gttcaggacccaaaaagg and R gcagagtcttgatcttggag, human F ctggctctttctctcttgtc
and R cgtctggttctctttctcag.
9Protein Extraction, Western Blotting and Antibodies
Tissues and cell culture were lysed in buffer 1% NP40, 1mM EDTA, 50mM
Tris-HCl pH 7.5, 150 mM NaCl, supplemented with CompleteTM protease
inhibitors cocktail (Roche Diagnostic Corp.). Total proteins were separated
by SDS-PAGE and transferred to nitrocellulose membranes (Biorad).
Membranes were blocked with 5% non-fat milk and incubated with
antibodies against Hand1 and Tubulin. Hand1 antibody was a generous gift
from Dr. Peter Cserjesi (New Orleans, USA). Bound antibody was detected
by the appropriate secondary antibody and revealed with an enhanced
chemiluminescence system (Amersham-Pharmacia Biotech).
Electrophoretic Mobility Shift Assay
The production of recombinant proteins was previously described (20). Five
or 20 ng of recombinant protein were incubated with radiolabeled double-
strand oligonucleotides, corresponding to the region spanning bases  -2658
to -2688 of the 5’ untranslated region of the murine Hand1 promoter  (5’-
atttattttattttaactaattaattaataa-3’). A 200-fold excess of specific unlabeled
competitor oligonucleotide was added. The same oligonucleotides were also
used in binding assays with total extract from wild type and hmga1-
knockout murine ES cells. 8 µg of extracts were incubated in 20 mM Hepes
pH 7.6, 40 mM KCl, 0.1 mM EDTA, 0.5 mM MgCl2, 0.5 mM DTT, 0.1
mM PMSF in a volume of 20 µl containing 1 µg of poly(dC-dG), 2 µg BSA
and 10% glycerol, for 10 min at room temperature. Binding reactions were
incubated for 10 min after addition of 2.5 fmol of 32P-end labeled
oligonucleotides (specific activity, 8,000 to 20,000 cpm/fmol). The DNA-
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protein complexes were resolved on 6% non-denaturing acrylamide gels and
visualized by exposure to autoradiographic films.
Chromatin immunoprecipitation
Approximately 3x107 wild type, hmga1 +/- and -/- ES cells were grown on
75 cm2 dishes. Chromatin immunoprecipitation was performed as previously
described (21). Input and immunoprecipitated DNA were analyzed by PCR
for the presence of Hand1 promoter sequence spanning –2424 to -2927. The
primers used were 5'- cttggtgacaagcacctt-3’ (forward) and 5'-
ctgagatcccagatcactca-3’ (reverse).
Methylation analysis using bisulphite genomic sequencing
The promoter region of human HAND1 gene was analyzed for CG content; a
CpG island was determined based on a 200-bp length of DNA with a CG
content of >50% and a CpG/GpC ratio of >0.5, using CpGplot program,
available at http://www.ebi.ac.uk/emboss/cpgplot/. Bisulphite genomic
sequencing was used to analyze the methylation patterns of individual DNA
molecules. Sodium bisulphite conversion of genomic DNA (about 200 ng
for each conversion) was obtained using EZ DNA Methylation Kit
(ZYMO Research) following the manufacturer's instructions. The CpG
islands identified as described previously were then PCR amplified using the
following primers: Pre-Nested PCR 3FHand (-461 to -430)
11
gtagagtagttggagttygggattgggaattg, 3RHand (+180 to +211)
ctccatacrccccaaaaactaccraaaaccac. Nested PCR 3FnHand (- 275 to -249)
ggagggggtggtagtaatagtttaggg, 3 R n H a n d  ( + 1 7 0  t o  + 2 0 1 )
ccccaaaaactaccraaaaccacctataaactc. PCR reactions were carried out using
FastStart Taq DNA polymerase (Roche) under the following conditions: 1)
Pre-nested PCRs were normally carried out on 10 ng of bisulphite treated
DNA in a final reaction volume of 50 ml, using standard conditions with 1,5
min at 95°C, followed by 5 cycles of  30 sec at 95°C, 30 sec at 59°C, and 40
sec at 72°C,  then 25 cycles of 30 sec at 95°C, 30 sec at 57°C, and 40 sec at
72°C, then a final elongation of 6 min at 72°C before holding at 4°C. 2)
Nested PCRs were performed in the same conditions, using 5 ml of the
corresponding pre-nested PCRs in a final reaction volume of 50 ml. PCR
final products (477 bp) were then cloned into the pGEM-Teasy vector
provided by Promega pGEM-T Easy Vector System II, following the
supplier’s procedures. The positive screened colonies contained the unique
sequence of one individual DNA molecule. The plasmidic DNA from the
selected positive colonies containing vectors with the insert was purified
using the Qiagen plasmid Mini Kit. The purified plasmids were sequenced in
both directions using T7 and Sp6 primers. 20 independent clones for each
genomic preparation and fragment of interest were sequenced to determine
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the methylation pattern of individual molecules. Sequencing was performed
at the CEINGE Sequencing Core Facility.
SNP-based Loss of Heterozygosity analysis
We performed LOH analysis using Single Nucleotide Polymorphisms
(SNP). To identify the SNPs scattered in the genetic locus of HAND1, we
input HAND1 human gene name in the SNP database of NCBI and we found
eight SNPs. The primers, SNP reference and alleles are: F-
cgaaataggcaaacaggctc and R- aaagctcatccagggacga for rs924581 (A/G); F-
gaagacccgatctgttttacct and R- cttcaaggctgaactcaagaa for rs4370323 (A/G),
rs1846966 (C/G), rs11748765 (A/T); F- cgctgttaatgctctcagt and R-
gtaaaacctgggatagcca for rs6880185 (A/G), rs13171812 (C/T), rs993098
(A/C), rs3822714 (A/G). The primers used for PCR was also used for
sequencing assays. PCR was performed using HotMaster Taq DNA
Polimerase (Eppendorf AG, Germany) in a final volume of 25 µl. For
amplification reaction we used 50 ng of genomic DNA, 0,5 unit of
Hotmaster Taq DNA polymerase, a final concentration of each primer of 0.2
µM and 0.2mM of dNTPs and 2,5 µ l of 10x HotMaster Taq DNA
Polimerase Buffer with Mg2+. The conditions used for PCR was an initial
denaturation at 94°C for 2 min, 35 cycles of 94°C for 20 sec, 58°C for 10
sec, 70°C for 40 sec and a final extension of 5 min at 70°C. After
amplification the size and quality of amplicons was checked loading 5 µl of
reactions on agarose gel. 20 µl of each PCR was sequenced with specific
forward and reverse primers used for amplification reaction.
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RESULTS
Loss of HMGA1 correlates with an increased Hand1 expression in
murine ES cells, heart and thyroid tissues
Microarray analysis of the expression profile of embryonic stem (ES) cells
bearing one or two disrupted hmga1 alleles revealed the Hand1 gene as a
gene likely negatively regulated by HMGA1. In fact, the chip showed a 3,8
fold-change for heterozygous cells and a 14 fold-change for homozygous
cells (Martinez et al. 04). Therefore, our first aim was to validate the results
obtained by microarray analysis by semiquantitative and quantitative RT-
PCR (Figure 1A and 1B). These analyses confirmed the differential
expression between wild type and hmga1-knockout ES cells. They clearly
showed that regulation of Hand1 expression was HMGA1-dose dependent
since an intermediate level of Hand1 expression was observed in the
heterozygous ES cells.
 The analysis of the Hand1 expression in heart and thyroid tissues derived
from hmga1-knockout mice revealed the same kind of regulation by
HMGA1 (Figure 1C). Conversely, no changes in Hand1 expression were
observed depending on the Hmga1 expression when embryonic fibroblasts,
brain, spleen, liver, and thymus from hmga1 minus mice were analyzed
(data not shown) This confirmed that HMGA1-mediated gene regulation
depends on the cellular context.
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Interestingly, when we analyzed same tissues from the Hmga2 minus mice,
no changes in Hand1 expression were observed indicating that Hand1
regulation was HMGA1 specific.
HMGA1 proteins bind to murine Hand1 promoter in vitro and in vivo
To evaluate whether the differential Hand1 gene expression was a direct
effect of HMGA1 we performed an electrophoretic mobility shift assay
(EMSA). In particular, we analyzed a region spanning nucleotides -2658 to -
2688 of the 5’ untranslated region of the murine Hand1 gene containing AT-
rich putative HMGA1 binding sites. As shown in Figure 2A, a recombinant
HMGA1 protein was able to bind directly to this region. Binding specificity
was demonstrated by competition experiments showing loss of binding with
the addition of 200-fold molar excess of specific, unlabeled oligonucleotides.
Subsequently, we performed binding assays with total extract from wild type
and hmga1-knockout ES cells. A specific complex with a mobility
corresponding to the HMGA1 proteins was present in extracts from wild type
mice while it was absent in extracts from homozygous hmga1-knockout ES
cells (Figure 2 B). To verify that HMGA1 proteins bind to Hand1 promoter
in vivo we performed experiments of chromatin immunoprecipitation. Anti-
HMGA1 antibodies precipitated Hand1 promoter from hmga1 +/+ and +/- ES
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cells, but not from hmga1 -/- ES cells (Figure 2C). Moreover, no
amplification was observed in samples immunoprecipitated with a not related
antibody.
HMGA1 proteins repress murine Hand1 promoter
In order to investigate the functional effect of HMGA1 proteins on Hand1
promoter, we transiently transfected the rat thyroid cells, FRTL-5, that
express low levels of HMGA1 with a construct expressing the luciferase
gene under the control of the mouse Hand1 promoter region -2424 – -2728.
As shown in Figure 3A, when the HMGA1 expression vector was
transfected, a reduction of the luciferase activity was observed in a dose-
dependent manner. No decrease in Hand1 promoter activity was obtained
when the cells were transfected with a construct expressing HMGA2 the
other member of the HMGA family. Then, we generated two point
mutations in the putative binding site for the HMGA1 protein replacing
adenine -2681 and thymidine -2682 with two guanines. Over-expression of
HMGA1 was able to reduce the activity of the wild type construct, but it
completely failed in its inhibitory effect if the HMGA1 binding site was
mutated (Figure 3B).
Hand1 expression is drastically decreased in thyroid cell transformation
The HMGA1 proteins are over-expressed in several malignant neoplasias.
Then, in order to evaluate a possible role of Hand1 regulation by HMGA1 in
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cell transformation, we analyzed, by RT-PCR, the expression of Hand1 in
FRTL-5 normal thyroid cells which do not express significant levels of
HMGA1, in the same cells transformed by the Kirsten murine sarcoma virus,
which express high levels of HMGA1 (FRTL-5 –KiMSV) and in the FRTL-
5 cells which have been transfected with an hmga1 antisense construct
before being infected by Ki-MSV (FRTL-5-HMGA1as-KiMSV cells), and
then do not express the HMGA1 proteins. A significant Hand1 expression
was observed in the cells which do not express the HMGA1 proteins, such
as the FRTL-5 and FRTL-5-HMGA1as-KiMSV), whereas no expression
was observed in the FRTL-KiMSV cells expressing high HMGA1 levels
(Figure 4A).
These results confirm an inverse correlation between HMGA1 and Hand1
expression also in transformed cells.
Subsequently, we analyzed the expression of HMGA1 and Hand1 in a panel
of 13 human thyroid carcinoma-derived cell lines. An inverse correlation
between HMGA1 and Hand1 expression levels was observed. In fact,
HMGA1 expression was increased in all tumor-derived cell lines tested
when compared to normal primary cultured cells used as a control (Figure
4B); conversely, HAND1 mRNA expression level was much lower in all of
the thyroid carcinoma cell lines compared to normal cells (Figure 4B).
Therefore, Finally, Hand1 and HMGA1 gene expression was examined in
20 surgically removed human thyroid carcinomas by real time PCR (Figure
4C). Again, an inverse correlation between HMGA1 and Hand1 mRNA
levels was observed.  In fact, HMGA1 mRNA levels were almost
undetectable in normal thyroid tissue, whereas they were highly expressed in
most of the tumors analyzed. In contrast, Hand1 expression was strongly
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diminished in almost all of the tumor samples compared to normal thyroid
tissue.
Down-regulation of HAND1 expression in human thyroid carcinomas
is not associated to LOH and DNA methylation
We have analyzed the methylation status of thyroid carcinoma samples
showing the lowest HAND1 expression and in normal thyroid. We have
analyzed two regions of the 5’ untranslated region of the human HAND1
gene, described under Materials and Methods.
These regions were unmethylated in normal and carcinoma samples
indicating that the silencing of Hand1 gene in neoplastic samples is not
dependent on the gene hypermethylation.
Therefore, we analyzed thyroid carcinoma samples for Loss of
Heterozygosity (LOH). We analyzed eight Single Nucleotide
Polymorphisms: however no LOH was found.
Therefore, these results would suggest that it is likely that the HMGA1-
negative regulation plays a critical role in Hand1 gene suppression in human
thyroid carcinomas.
Restoration of Hand1 gene expression inhibits the growth of thyroid
carcinoma cell lines.
To determine whether loss of Hand1 gene expression affects thyroid
carcinogenesis, we evaluated the growth rate of thyroid carcinoma cell lines in
which Hand1 expression had been restored. To this aim we carried out a
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colony forming assay with cell lines obtained from human thyroid carcinomas
(NPA, FB-2) after transfection with the vector carrying the Hand1 gene or the
empty backbone vector. The colonies were scored after two weeks. Cells
transfected with the Hand1 gene generated a lower number of colonies than
did cells transfected with the backbone vector (Figure 6).
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DISCUSSION
In our previous work we identified HMGA1-regulated genes analyzing by
microarrays the expression profile of embryonic stem (ES) cells bearing one
or two disrupted hmga1 alleles. We found the Hand1 gene, a transcription
factor crucial for differentiation of trophoblast giant cells and heart
development, negatively regulated by HMGA1 proteins with a high fold
change in the ES hmga1  minus cells in comparison to the wild type
(Martinez). Moreover, we examined the consequences of disrupting the
Hmga1  gene in mice and we reported that both heterozygous and
homozygous Hmga1-null mice show cardiac hypertrophy due to the direct
role of HMGA1 on cardiomyocytic cell growth regulation (Fedele).
Here, we focused our attention on Hand1 gene regulation by HMGA1
proteins. We validated the microarray results by semiquantitative and
quantitative RT-PCR in ES cells. As in microarrays, we found that Hand1
expression displayed dose-dependency, the phenotype of heterozygous cells
was intermediate between those of wild type and homozygous knockout
cells. When we extended the analysis to embryonic fibroblasts and diverse
tissues we found an increased Hand1 expression only in heart and thyroid
from hmga1-knockout mice respect to wild type. This results indicated that
HMGA1-mediated Hand1 regulation depends on the cellular context.
When we analyzed by RT-PCR the expression of Hand1 in MEF and adult
tissues taken from hmga2-knockout mice, we found no changes between
wild type and knockout cells and tissues. This result indicates that hand1 is
probably not regulated by HMGA2. In fact, by Luciferase assay, we did not
found an alteration in promoter activity when we included an Hmga2
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expression construct. This specific responsiveness to HMGA1 and not
HMGA2 confirms that even though HMGA1 and HMGA2 have a similar
structure and expression profile (high during embryogenesis and neoplastic
tissue), they exert different functions.  This is consistent with our previous
findings: the phenotype of the hmga1- and hmga2-knockout mice is
divergent: a reduction in size and fat tissue in hmga2-null mice, and cardiac
hypertrophy and B-cell lymphomas in hmga1-null mice (Fedele ).
We wanted to know if HMGA proteins could regulate also Hand2, a gene
that belongs to the Twist subfamily of class B bHLH transcription factors as
Hand1, and shares 87% homology in bHLH region. We did not find altered
expression of Hand2 neither in ES cells, MEF, nor in adult tissues from
hmga1- and hmga2-knockout mice (data not shown).
To demonstrate a direct effect of HMGA1 on Hand1  regulation, we
performed mobility shift assay and chromatin immunoprecipitation
experiments. We show that the HMGA1 proteins bind to the Hand1
upstream regulating region, in vitro and in vivo.  We performed Luciferase
assay to demonstrate a reduction in Hand1 promoter activity caused by
HMGA1 expression. Since Hand1 plays a major role in heart development,
the HMGA1-mediated regulation of Hand1 suggests a possible mechanism
by which loss of HMGA1 expression may lead to cardiac hypertrophy.
Our next aim was study the role of Hand1 in thyroid transformation. The
rationale for this study was that HMGA1 are over-expressed in several
malignant neoplasias and have a major role in transformation, since we have
demonstrated that Hand1 is regulated by HMGA1 proteins, we suspected
that Hand1 could have a role in transformation. Moreover, in literature it has
22
been described Hand1 silencing due to promoter methylation in pancreas,
stomach and ovarian carcinomas (Ushijima).
First of all, we study by RT-PCR Hand1 expression in a cell system
constituted by normal rat thyroid cells (FRTL-5) that do not express
HMGA1 proteins, the same cells malignantly transformed by the KiMSV
(FRTL-5-KiMSV) that express high HMGA1 levels and FRTL-5-KiMSV
cells in which the synthesis of the HMGA1 protein was blocked by an
antisense construct (FRTL-5-HMGA1as-KiMSV). We found Hand1
expression in cells that do not express HMGA1 and vice versa, confirming
an inverse correlation between HMGA1 and Hand1 expression. We found
same result when we analyzed by RT-PCR 12 human thyroid carcinoma-
derived cell lines and by real time PCR 20 human thyroid carcinomas
surgically removed. IHC …
We did not find alterations of DNA methylation of HAND1 gene in human
thyroid carcinomas, suggesting that Hand1 down-regulation is not mediated
by this phenomenon. We analyzed two regions of the 5’untranslated region
of the human HAND1 gene, one has been already described to be methylated
in some tumors and cancer cell lines (Ushijima). This discrepancy can be
explained by the fact that HMGA1-mediated gene regulation depends on the
cellular context, we have demonstrated that Hand1 is regulated by HMGA1
in some cell and tissues but not in others. Maybe, what is important is
Hand1-silencing, in some tumors this is accomplished by promoter
methylation and in another tumors this is accomplished by HMGA1-down-
regulation. Therefore we analyzed thyroid carcinoma samples for loss of
heterozygosity (LOH) however, no LOH was found. In literature, no micro
RNA targeting HAND1  have been found altered in human thyroid
23
carcinomas (Croce 2005 e Fusco 2006), so we exclude that the down-
regulation of Hand1 is due to micro RNA altered expression. For all these
reasons we hypothesize that direct Hand1 down-regulation exerted by
HMGA1 proteins may account for the malignant phenotype in human
thyroid carcinomas.
To confirm Hand1 role in transformation, we have performed Colony assay.
Upon re-expression of Hand1 in human thyroid carcinoma cell lines lacking
endogenous Hand1  expression, colony formation was significantly
compromised in two cell lines studied. ……
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LEGEND TO FIGURES
Figure 1
Hand1 expression in hmga1-knockout cells and tissues.
Semiquantitative (A,C) and quantitative (B) RT-PCR analyses for Hand1
expression were performed on RNA extracted from wild type (+/+), hmga1-
single knockout (+/-) and hmga1-double knockout (-/-) ES cells and tissues.
β-actine expression was evaluated as internal control.
Figure 2
HMGA1 binding to Hand1 upstream regulating region.
A) Electrophoretic mobility shift assay performed incubating radiolabeled
oligonucleotides spanning from -2658 to -2688 of the 5’ untranslated region
of the murine Hand1 gene with 5 or 20 ng of the recombinant HMGA1 as
indicated. To assess the specificity of the binding, a 200x molar excess of
unlabeled oligonucleotides were incubated as specific competitor. B)
Electrophoretic mobility shift assay performed with the same
oligonucleotides as in panel A, incubated with total extracts from wild type
(+/+) and hmga1-double knockout (-/-) ES cells. C) Chromatin
immunoprecipitation assay was performed on wild type, hmga1-single
knockout (+/-) and hmga1-double knockout (-/-) ES cells. The presence of -
2424 – -2927 sequence of the murine Hand1 promoter was detected by PCR.
Anti-HA was used as a negative immunoprecipitation control.
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Figure 3
Repression of Hand1 promoter activity by HMGA1 proteins.
(A) Effect of HMGA1 expression on the activity of murine Hand1 promoter
transfected in FRTL-5 cells. (B) the same promoter in which A -2681 and T
-2682 were replaced with G.
Figure 4
Hand1 expression in thyroid tumorigenesis.
Hand1 expression in transformed rat thyroid cells over-expressing HMGA1
(A). Sources of RNA are FRTL-5, rat thyroid epithelial cell line; FRTL-5-
KiMSV, FRTL-5 infected with the Kirsten murine sarcoma virus; FRTL-5-
HMGA1as-KiMSV, FRTL-5 transfected with a construct carrying HMGA1
mRNA in an antisense orientation, and then infected with the Kirsten murine
sarcoma virus. Hand1 expression in human thyroid carcinoma cell lines (B)
and human thyroid tumors (C). β-actine expression was used as internal
control of RNA quantity.
Figure 5
Analysis of Hand1 expression in normal and neoplastic thyroid tissues by
immunohistochemistry.
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Figure 6
Restoration of Hand1 gene expression reduces clonogenic capacities of
thyroid cancer cells.
N-PA and FB-2 thyroid cancer cell lines were transfected with a Hand1
expression vector (A,C,) or control vector (B,D,) and selected for neomycin
resistance. Three weeks after transfection plates were stained, counted, and
photographed.
